[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3379
1. Brady G, Macarthur GJ, Farrell PJ: Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J; 2008 Jul;84(993):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus and Burkitt lymphoma.
  • Burkitt lymphoma (BL) is an aggressive B-cell malignancy with endemic, sporadic and immunodeficiency-associated variants.
  • It has been known for many years that the fundamental transforming event in BL is the translocation of the MYC gene, and the events that bring about this translocation and those that allow cells to survive with the constitutive expression of MYC have been the subject of intense investigation.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / genetics. Genes, myc / genetics
  • [MeSH-minor] Cell Survival. Humans. Malaria / complications. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716017.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 133
  •  go-up   go-down


2. Reich CG, Mohammadi MH, Alger BE: Endocannabinoid modulation of fear responses: learning and state-dependent performance effects. J Psychopharmacol; 2008 Sep;22(7):769-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By administering the CB1 receptor antagonist AM251 (5 mg/kg, i.p) to C57/Bl/6 mice at various times, we systematically identified the stages of learning and memory (i.e. acquisition, consolidation, recall and extinction) that are modulated by eCB signaling.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychopharmacology. 2006 Dec;31(12):2652-9 [16541083.001]
  • [Cites] Neurosci Biobehav Rev. 2005;29(8):1207-23 [16095698.001]
  • [Cites] Eur J Pharmacol. 2000 Sep 15;404(1-2):175-9 [10980277.001]
  • [Cites] J Neurosci. 2000 Dec 1;20(23):8932-42 [11102504.001]
  • [Cites] Psychopharmacology (Berl). 2002 Feb;159(4):379-87 [11823890.001]
  • [Cites] Nat Neurosci. 2002 Aug;5(8):723-4 [12080342.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):530-4 [12152079.001]
  • [Cites] Eur J Neurosci. 2002 Oct;16(7):1395-8 [12405999.001]
  • [Cites] Eur J Neurosci. 2003 Mar;17(6):1279-86 [12670316.001]
  • [Cites] Hippocampus. 2003;13(3):305-15 [12722971.001]
  • [Cites] Eur J Pharmacol. 2003 Sep 23;477(3):213-7 [14522359.001]
  • [Cites] JAMA. 2006 Feb 15;295(7):761-75 [16478899.001]
  • [Cites] Eur J Pharmacol. 2006 Jun 13;539(3):177-83 [16716290.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):304-11 [16569753.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6677-86 [16793875.001]
  • [Cites] Crit Rev Neurobiol. 2003;15(2):91-119 [14977366.001]
  • [Cites] Eur J Neurosci. 2004 Apr;19(7):1906-12 [15078564.001]
  • [Cites] Neurobiol Learn Mem. 2004 May;81(3):162-6 [15082017.001]
  • [Cites] J Neurosci. 2004 May 19;24(20):4787-95 [15152039.001]
  • [Cites] Neuron. 2004 Sep 30;44(1):75-91 [15450161.001]
  • [Cites] Learn Mem. 2004 Sep-Oct;11(5):485-94 [15466298.001]
  • [Cites] Pavlov J Biol Sci. 1980 Oct-Dec;15(4):177-82 [7208128.001]
  • [Cites] Psychopharmacology (Berl). 1996 Apr;124(4):315-22 [8739546.001]
  • [Cites] Eur J Pharmacol. 1996 Jul 4;307(3):331-8 [8836622.001]
  • [Cites] Psychopharmacology (Berl). 1996 Jul;126(2):165-72 [8856836.001]
  • [Cites] Neuroreport. 1997 Jan 20;8(2):491-6 [9080435.001]
  • [Cites] Behav Brain Res. 1998 Oct;95(2):179-89 [9806438.001]
  • [Cites] Psychopharmacology (Berl). 1998 Nov;140(1):11-9 [9862397.001]
  • [Cites] Prog Neurobiol. 1999 Jul;58(4):315-48 [10368032.001]
  • [Cites] Eur J Pharmacol. 1999 Aug 20;379(1):R1-2 [10499380.001]
  • [Cites] Biol Psychiatry. 2005 Feb 1;57(3):261-7 [15691527.001]
  • [Cites] Neuropsychopharmacology. 2005 Mar;30(3):508-15 [15525997.001]
  • [Cites] Neuropsychopharmacology. 2005 Mar;30(3):516-24 [15637635.001]
  • [Cites] Neurobiol Learn Mem. 2005 Mar;83(2):119-24 [15721795.001]
  • [Cites] Neurosci Lett. 2005 Jun 3;380(3):270-5 [15862900.001]
  • [Cites] Psychopharmacology (Berl). 2005 Jun;179(4):863-72 [15619104.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):331-42 [15927244.001]
  • [Cites] Neuroscience. 2000;95(1):5-7 [10619457.001]
  • (PMID = 18308796.001).
  • [ISSN] 0269-8811
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS030219; United States / NINDS NIH HHS / NS / NS007375-12; United States / NINDS NIH HHS / NS / NS030219-12; United States / NINDS NIH HHS / NS / R01 NS30219; United States / NINDS NIH HHS / NS / NS07375; United States / NINDS NIH HHS / NS / T32 NS007375-12; United States / NIDA NIH HHS / DA / R01 DA014625-08; United States / NINDS NIH HHS / NS / R01 NS030219-12; United States / NIDCR NIH HHS / DE / R01 DE14625; United States / NIDA NIH HHS / DA / R01 DA014625; United States / NINDS NIH HHS / NS / T32 NS007375; United States / NIDA NIH HHS / DA / DA014625-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AM 251; 0 / Cannabinoid Receptor Modulators; 0 / Endocannabinoids; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1
  • [Other-IDs] NLM/ NIHMS217683; NLM/ PMC2906780
  •  go-up   go-down


3. Thomassin S, Jobin MP, Schmitt P: The acid tolerance response of Bacillus cereus ATCC14579 is dependent on culture pH, growth rate and intracellular pH. Arch Microbiol; 2006 Sep;186(3):229-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemolysin BL and non-haemolytic enterotoxin production were both influenced by pH(o) and micro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906407.001).
  • [ISSN] 0302-8933
  • [Journal-full-title] Archives of microbiology
  • [ISO-abbreviation] Arch. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acids; 0 / Culture Media; 0 / Enterotoxins
  •  go-up   go-down


Advertisement
4. Romero Gómez MP, García Rodríguez J: [Invasive fungal infection in a patient with Burkitt lymphoma]. Rev Iberoam Micol; 2010 Oct-Dec;27(4):214-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive fungal infection in a patient with Burkitt lymphoma].
  • [Transliterated title] Infección fúngica invasora en paciente con linfoma de Burkitt.
  • [MeSH-major] Burkitt Lymphoma / complications. Intestinal Diseases / complications. Intestinal Diseases / microbiology. Mycoses / complications. Scedosporium

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20674763.001).
  • [ISSN] 2173-9188
  • [Journal-full-title] Revista iberoamericana de micología
  • [ISO-abbreviation] Rev Iberoam Micol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


5. Yao L, Chen ZX, Cen JN, Liang JY, He J, Qi XF, Shen HJ: [Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols]. Zhonghua Xue Ye Xue Za Zhi; 2008 Oct;29(10):676-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols].
  • OBJECTIVE: To provide the evidence of RQ-PCR-based assessment of minimal residual disease (MRD), the clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements were identified in newly diagnosed adult patients with acute lymphoblastic leukemia (ALL) by multiplex PCR protocols.
  • METHODS: Forty newly diagnosed adult patients with B-lineage (B-) and T cell (T-) ALL were involved in this study.
  • CONCLUSIONS: The detection rate of clonal rearrangements using the BIOMED-2 14 multiplex PCR tubes is high, which can detect virtually all clonal B and T-cell proliferations.
  • It can be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoglobulins / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176062.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


6. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood; 2006 Feb 1;107(3):1149-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel therapeutic agents paramount.
  • Treated cells showed a dramatic decrease in cell proliferation and an increase in apoptotic cells, compared to untreated cells.
  • We treated a total of 68 mice generated from the same patient samples with CCI-779 after establishment of disease.
  • We performed immunoblots to validate the inhibition of the mTOR signaling intermediate phospho-S6 in human ALL, finding down-regulation of this target in xenografted human ALL exposed to CCI-779.
  • We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 [6501094.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):227 [2568561.001]
  • [Cites] Science. 1991 Jan 18;251(4991):283-7 [1702904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4441-5 [8183928.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1116-23 [7913512.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):907-13 [9508172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5033-8 [9560223.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):143-9 [9720724.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):718-21 [9722298.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Stem Cells. 2004;22(6):1111-20 [15536200.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2825-31 [15805283.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1614-20 [10995008.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):3-16 [11135052.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):249-58 [11566616.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8 [11583941.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2121-8 [11597394.001]
  • [Cites] Blood. 2002 Jul 15;100(2):654-60 [12091361.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2887-92 [12912932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1420-4 [15365568.001]
  • [Cites] Leuk Res. 1986;10(8):1007-13 [3528680.001]
  • (PMID = 16195324.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K08 CA104882; United States / NCI NIH HHS / CA / K08 CA104882-01A1; United States / NCI NIH HHS / CA / CA82156; United States / NCI NIH HHS / CA / CA104882-01A1; United States / NCI NIH HHS / CA / CA96696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1895910
  •  go-up   go-down


7. Merks JH, Caron HN, Hennekam RC: High incidence of malformation syndromes in a series of 1,073 children with cancer. Am J Med Genet A; 2005 Apr 15;134A(2):132-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Constitutional molecular defects are known to play a role in oncogenesis, as shown by the increased incidence of embryonic cancers in children with Beckwith-Wiedemann syndrome (BWS) or of leukemia in children with Down syndrome.
  • To establish the incidence and spectrum of malformation syndromes associated with childhood cancer we performed a clinical morphological examination on a series of 1,073 children with cancer.
  • We diagnosed a syndrome in 42 patients (3.9%) and suspected the presence of a syndrome in another 35 patients (3.3%), for a total of 7.2%.
  • We describe new syndrome-tumor associations in several entities: cleidocranial dysostosis (Wilms tumor), Bardet-Biedl syndrome (BBS) (acute lymphoblastic leukemia), Kabuki syndrome (neuroblastoma), LEOPARD syndrome (neuroblastoma), Poland anomaly (osteosarcoma; Hodgkin disease), and blepharophimosis epicanthus inversus syndrome (Burkitt lymphoma).
  • We propose that all children with a malignancy should be examined by a clinical geneticist or a pediatrician skilled in clinical morphology to determine if the patients have a malformation syndrome.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Comorbidity. DNA Methylation. Female. Genetic Predisposition to Disease / genetics. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Mutation. Netherlands / epidemiology. Syndrome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Am J Med Genet A. 2006 Apr 15;140(8):932 [16532461.001]
  • (PMID = 15712196.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol; 2009 Dec;27(4):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
  • Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an "aggressive B-cell non-Hodgkin's lymphoma", characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene.
  • The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL).
  • While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic and cytogenetics intermediate between DLBCL and BL, and cannot be classified with certainty in these categories.
  • Distinguishing between BL and DLBCL is critical, as the two diseases require different management.
  • This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of "B-cell lymphoma, unclassificable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma", now listed in the updated WHO classification.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19670467.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


9. Patuto N, Strebel BM, Schmitt AM, Tutuian R: A gastric moonscape: lymph node penetration from subsequent Burkitt lymphoma after treatment of Hodgkin's lymphoma. Gastrointest Endosc; 2010 May;71(6):1089-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastric moonscape: lymph node penetration from subsequent Burkitt lymphoma after treatment of Hodgkin's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Hodgkin Disease / therapy. Liver Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Gastroscopy. Humans. Liver / pathology. Lymph Nodes / pathology. Male. Middle Aged. Pancreas / pathology. Stomach / pathology. Stomach Ulcer / diagnosis. Ultrasonography


10. Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B: Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography. AJR Am J Roentgenol; 2006 Apr;186(4):1029-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography.
  • [MeSH-major] Breast Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Mammography. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554574.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Koyama Y, Yamazaki K, Yamada M, Asou A, Furuya Y, Ishida Y: Cytological and cytogenetic approaches to diagnosis of primary intrapelvic Burkitt lymphoma involving the urinary bladder. Cytopathology; 2009 Aug;20(4):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological and cytogenetic approaches to diagnosis of primary intrapelvic Burkitt lymphoma involving the urinary bladder.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Urinary Bladder / pathology. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416312.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Dormady SP, Mariappan MR, Kao D, Gotlib J: Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. J Clin Oncol; 2006 Sep 20;24(27):4515-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Flow Cytometry. Neoplasm Recurrence, Local / diagnosis. Urine / cytology. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Kidney Neoplasms / diagnosis. Male. Salvage Therapy / methods. Ureteral Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Li J, Han CH, Cheng XH, Zhu GX, Gong XH, Hou WG, Bao YH, Xu YG: [Observation on therapeutic effects of elongated needle therapy on dysuria induced by benign prostatic hyperplasia]. Zhongguo Zhen Jiu; 2008 Oct;28(10):707-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acupuncture was given at bilateral Zhibian (BL 54) and Zhongji (CV 3) in the two groups, once daily, 5 sessions constituting one course, with a 2-day interval between two courses.


14. Mori M, Tabata S, Hashimoto H, Inoue D, Kimura T, Shimoji S, Nagai Y, Togami K, Itoh K, Matsushita A, Nagai K, Ikeda E, Kimoto N, Uryuhara K, Kaihara S, Imai Y, Itoh M, Takahashi T: Successful living donor liver transplantation for severe hepatic GVHD histologically resembling autoimmune hepatitis after bone marrow transplantation from the same sibling donor. Transpl Int; 2010 May 1;23(5):e1-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 30-year-old woman developed severe liver dysfunction 1 year after bone marrow transplantation (BMT) from an HLA-identical sibling donor for B lymphoblastic leukemia (B-ALL) during the tapering of cyclosporin A.
  • AIH-like hepatic graft-versus-host disease (GVHD) has not been documented.
  • [MeSH-major] Bone Marrow Transplantation / methods. Graft vs Host Disease / etiology. Hepatitis, Autoimmune / immunology. Liver Transplantation / methods. Living Donors
  • [MeSH-minor] Adult. Biopsy. Female. HLA Antigens / chemistry. Hematopoiesis. Humans. Hypergammaglobulinemia / immunology. Immunophenotyping. Immunosuppressive Agents / therapeutic use. Leukemia, Biphenotypic, Acute / complications. Leukemia, Biphenotypic, Acute / therapy


15. Choi JY, Kim KH, Choy KC, Oh KT, Kim KN: Photocatalytic antibacterial effect of TiO(2) film formed on Ti and TiAg exposed to Lactobacillus acidophilus. J Biomed Mater Res B Appl Biomater; 2007 Feb;80(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When irradiated under near-ultraviolet (UV) light, TiO(2) exhibits strong bactericidal activity.
  • Bacterial solutions were pipetted onto the TiO(2)-coated specimen and illuminated with UVA (2 x 15 W, black light, 356 nm) up to 100 min and the reaction solutions were incubated to count the colony-forming units.

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. TITANIUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 16850466.001).
  • [ISSN] 1552-4973
  • [Journal-full-title] Journal of biomedical materials research. Part B, Applied biomaterials
  • [ISO-abbreviation] J. Biomed. Mater. Res. Part B Appl. Biomater.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alloys; 0 / Anti-Bacterial Agents; 0 / Dental Materials; 15FIX9V2JP / titanium dioxide; 3M4G523W1G / Silver; D1JT611TNE / Titanium
  •  go-up   go-down


16. Ben H, Li L, Gao XY, He W, Rong PJ: [Comparison of NO contents and cutaneous electric conduction quantity at the acupoints and the non-acupoints]. Zhen Ci Yan Jiu; 2009 Dec;34(6):383-6, 392
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of NO contents and cutaneous electric conduction quantity at the acupoints and the non-acupoints].
  • OBJECTIVE: To observe the effects of acupuncture at acupoints and non-acupoints on the subcutaneous nitric oxide (NO) content and skin electric conduction quantity.
  • METHODS: A total of 40 healthy volunteers (half males and half females at ages of 25-45 years) signed informed consent for detection of NO (n=20) contents and skin electric conduction quantity (electric current, EC, n=20) of the acupoint and non-acupoint area.
  • The two series of 20 subjects were equally randomized into acupuncture group and non-acupuncture group, respectively.
  • Jianshi (PC 5), Chengshan (BL 57) were punctured with filiform needles, with the needles twirled for 2 min and retained for 20 min.
  • Dermal electric current were detected by using Dermatron (electrodermal screening device), and NO contents in the microdialysis fluid collected from the subcutaneous tissues of Ximen (PC 4), Chengjin (BL 56) and non-acupoints 1.0 approximately 1.5 cm lateral to PC 4 and BL 56 were detected by chemiluminescence technique. RESULTS:.
  • (1) NO contents of PC 4, BL 56 and two non-acupoint regions in acupuncture group were all significantly higher than those of two acupoints and two non-acupoints in non-acupuncture group (P<0.05).
  • In acupuncture group, the NO contents of both PC 4 and BL 56 were strikingly higher than those of two non-acupoints (P<0.05).
  • In non-acupuncture group there were no significant differences between PC 4 and non-acupoint and between BL 56 and non-acupoint (P>0.05). (2) The skin electric current values of PC 4 and BL 56 were significantly higher than those of two corresponding non-acupoints in both acupuncture and non-acupuncture groups (P<0.05).
  • Following acupuncture stimulation, an increasing tendency was found in the electric current in comparison with non-acupuncture group but without significance (P>0.05).
  • CONCLUSION: Acupuncture stimulation can upregulate dermal NO content and and the skin electric current of acupoint region was significantly higher than that of non-acupoint in healthy subjects, suggesting an increase of potential activity after acupuncture.

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209973.001).
  • [ISSN] 1000-0607
  • [Journal-full-title] Zhen ci yan jiu = Acupuncture research
  • [ISO-abbreviation] Zhen Ci Yan Jiu
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


17. Andronescu M, Condon A, Hoos HH, Mathews DH, Murphy KP: Computational approaches for RNA energy parameter estimation. RNA; 2010 Dec;16(12):2304-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods for efficient and accurate prediction of RNA structure are increasingly valuable, given the current rapid advances in understanding the diverse functions of RNA molecules in the cell.
  • (1) the Constraint Generation (CG) method, which iteratively generates constraints that enforce known structures to have energies lower than other structures for the same molecule; and (2) the Boltzmann Likelihood (BL) method, which infers a set of RNA free-energy parameters that maximize the conditional likelihood of a set of reference RNA structures.

  • MedlinePlus Health Information. consumer health - Health Statistics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):i68-76 [18586747.001]
  • [Cites] Nat New Biol. 1973 Nov 14;246(150):40-1 [4519026.001]
  • [Cites] Biochemistry. 1986 Jun 3;25(11):3209-13 [3730356.001]
  • [Cites] Biochemistry. 1986 Sep 23;25(19):5755-9 [3778880.001]
  • [Cites] Biochemistry. 1987 Jul 14;26(14):4554-8 [2444250.001]
  • [Cites] Nucleic Acids Res. 1988 Dec 23;16(24):11725-35 [3211748.001]
  • [Cites] Science. 1989 Apr 7;244(4900):48-52 [2468181.001]
  • [Cites] Biochemistry. 1989 Jan 24;28(2):742-7 [2469461.001]
  • [Cites] Methods Enzymol. 1989;180:227-39 [2482415.001]
  • [Cites] Biochemistry. 1990 Jan 9;29(1):278-85 [2322546.001]
  • [Cites] Biopolymers. 1990 May-Jun;29(6-7):1105-19 [1695107.001]
  • [Cites] Biochemistry. 1990 Sep 18;29(37):8813-9 [2271557.001]
  • [Cites] Biochemistry. 1991 Jul 2;30(26):6428-36 [1711369.001]
  • [Cites] Biochemistry. 1991 Aug 20;30(33):8242-51 [1714301.001]
  • [Cites] Biochemistry. 1991 Nov 19;30(46):11124-32 [1718426.001]
  • [Cites] Nucleic Acids Res. 1991 Nov 11;19(21):5901-5 [1719483.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):819-24 [1371866.001]
  • [Cites] Biophys J. 1992 Sep;63(3):751-9 [1384741.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 11;21(16):3845-9 [7690127.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14289-96 [7524674.001]
  • [Cites] Nucleic Acids Res. 1995 Jan 25;23(2):302-6 [7532297.001]
  • [Cites] Biochemistry. 1995 Mar 14;34(10):3204-11 [7533535.001]
  • [Cites] Biochemistry. 1994 Sep 20;33(37):11349-54 [7537087.001]
  • [Cites] Biochemistry. 1999 Oct 26;38(43):14214-23 [10571995.001]
  • [Cites] RNA. 1999 Nov;5(11):1458-69 [10580474.001]
  • [Cites] RNA. 2000 Mar;6(3):325-38 [10744018.001]
  • [Cites] RNA. 2000 Apr;6(4):608-15 [10786851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5784-9 [10823936.001]
  • [Cites] Biochemistry. 2000 Aug 8;39(31):9257-74 [10924119.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2478-83 [11327869.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23):6971-81 [11389613.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9736-41 [11470904.001]
  • [Cites] Biochemistry. 2001 Sep 25;40(38):11509-17 [11560499.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Biochemistry. 2002 Jan 22;41(3):869-80 [11790109.001]
  • [Cites] Biochemistry. 2002 Aug 20;41(33):10406-17 [12173927.001]
  • [Cites] Biochemistry. 2002 Oct 8;41(40):12062-75 [12356306.001]
  • [Cites] Biochemistry. 1996 Oct 22;35(42):13586-96 [8885838.001]
  • [Cites] Biochemistry. 1996 Nov 12;35(45):14077-89 [8916893.001]
  • [Cites] Biochemistry. 1996 Dec 17;35(50):16105-9 [8973181.001]
  • [Cites] Biochemistry. 1997 Apr 22;36(16):4844-51 [9125504.001]
  • [Cites] Biochemistry. 1997 Jul 1;36(26):8030-8 [9201950.001]
  • [Cites] Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W70-4 [18424795.001]
  • [Cites] J Am Chem Soc. 2008 Aug 6;130(31):10233-9 [18613678.001]
  • [Cites] J Mol Biol. 2008 Sep 12;381(4):1055-67 [18639245.001]
  • [Cites] BMC Bioinformatics. 2008;9:340 [18700982.001]
  • [Cites] Mol Syst Biol. 2008;4:224 [18956013.001]
  • [Cites] BMC Bioinformatics. 2008;9:474 [19014431.001]
  • [Cites] RNA. 2010 Jan;16(1):26-42 [19933322.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):489-91 [12520059.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3450-60 [12824344.001]
  • [Cites] BMC Bioinformatics. 2002;3:2 [11869452.001]
  • [Cites] Biochemistry. 2003 Dec 9;42(48):14184-96 [14640686.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):7280-301 [14654704.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15310-5 [14676318.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):360-5 [14691248.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):1824-8 [15037659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7287-92 [15123812.001]
  • [Cites] RNA. 2004 Aug;10(8):1178-90 [15272118.001]
  • [Cites] Biochemistry. 2004 Sep 21;43(37):11813-7 [15362866.001]
  • [Cites] RNA. 2004 Oct;10(10):1507-17 [15383676.001]
  • [Cites] Biochemistry. 2004 Oct 12;43(40):12865-76 [15461459.001]
  • [Cites] Biochemistry. 1997 Oct 14;36(41):12486-97 [9376353.001]
  • [Cites] Biochemistry. 1998 Jan 27;37(4):1094-100 [9454601.001]
  • [Cites] Biopolymers. 1997;44(3):309-19 [9591481.001]
  • [Cites] Biochemistry. 1998 Oct 20;37(42):14719-35 [9778347.001]
  • [Cites] Nucleic Acids Res. 1999 Jan 1;27(1):314 [9847214.001]
  • [Cites] Nucleic Acids Res. 1999 Feb 15;27(4):1118-25 [9927746.001]
  • [Cites] Biopolymers. 1999 Feb;49(2):145-65 [10070264.001]
  • [Cites] J Mol Biol. 1999 May 21;288(5):911-40 [10329189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10649-54 [10485880.001]
  • [Cites] Biochemistry. 2004 Dec 21;43(50):15822-37 [15595837.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D139-40 [15608164.001]
  • [Cites] J Mol Biol. 2005 Feb 4;345(5):987-1001 [15644199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2454-9 [15665081.001]
  • [Cites] Biochemistry. 2005 Mar 1;44(8):2845-56 [15723528.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):337-43 [15723047.001]
  • [Cites] RNA. 2005 Apr;11(4):512-6 [15769878.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1424-33 [16244657.001]
  • [Cites] Biochemistry. 2005 Dec 20;44(50):16710-7 [16342961.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D163-8 [16381838.001]
  • [Cites] Biochemistry. 2006 Feb 7;45(5):1400-7 [16445282.001]
  • [Cites] Bioinformatics. 2006 Feb 15;22(4):500-3 [16357029.001]
  • [Cites] RNA. 2006 Mar;12(3):323-31 [16495231.001]
  • [Cites] Biochemistry. 2006 Mar 28;45(12):4025-43 [16548530.001]
  • [Cites] BMC Bioinformatics. 2006;7:65 [16472402.001]
  • [Cites] Genome Res. 2006 Jul;16(7):885-9 [16751343.001]
  • [Cites] Nucleic Acids Res. 2006;34(11):3338-44 [16820533.001]
  • [Cites] Bioinformatics. 2006 Jul 15;22(14):e90-8 [16873527.001]
  • [Cites] BMC Bioinformatics. 2006;7:173 [16566836.001]
  • [Cites] Biochemistry. 2006 Oct 3;45(39):11776-89 [17002278.001]
  • [Cites] Nucleic Acids Res. 2006;34(17):4912-24 [16982646.001]
  • [Cites] Biochemistry. 2007 Feb 13;46(6):1511-22 [17279616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5830-5 [17389398.001]
  • [Cites] BMC Bioinformatics. 2007;8:130 [17445273.001]
  • [Cites] Nat Biotechnol. 2007 Jul;25(7):795-801 [17515909.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):i19-28 [17646296.001]
  • [Cites] PLoS Comput Biol. 2007 Oct;3(10):1896-908 [17937495.001]
  • [Cites] Biochemistry. 2007 Nov 20;46(46):13425-36 [17958380.001]
  • [Cites] Biochemistry. 2007 Dec 18;46(50):14715-24 [18020450.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(2):640-7 [18073195.001]
  • [Cites] Biochemistry. 2008 Apr 8;47(14):4329-36 [18330995.001]
  • [Cites] Nucleic Acids Res. 2008 Apr;36(7):2406-17 [18304945.001]
  • [Cites] PLoS Biol. 2008 Apr 29;6(4):e96 [18447581.001]
  • [Cites] J Mol Biol. 2008 May 23;379(1):160-73 [18440024.001]
  • (PMID = 20940338.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM076485; United States / NIGMS NIH HHS / GM / R01GM076485
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2995392
  •  go-up   go-down


18. Shirai S, Suzuki Y, Yoshinaga J, Mizumoto Y: Maternal exposure to low-level heavy metals during pregnancy and birth size. J Environ Sci Health A Tox Hazard Subst Environ Eng; 2010 Sep;45(11):1468-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The birthweight (BW), length (BL) and head circumference (HC) of the newborns delivered to the subjects were measured and relationship with urinary metal concentration was examined.
  • Stepwise multiple regression analysis using birth size as a dependent variable and urinary metal concentrations and covariates as independent variables extracted urinary Cd with a significant negative standardized partial regression coefficient (beta) for BW along with gestational age and maternal BMI.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. MOLYBDENUM .
  • Hazardous Substances Data Bank. TIN .
  • Hazardous Substances Data Bank. ANTIMONY, ELEMENTAL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. BERYLLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694885.001).
  • [ISSN] 1532-4117
  • [Journal-full-title] Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering
  • [ISO-abbreviation] J Environ Sci Health A Tox Hazard Subst Environ Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metals, Heavy; 00BH33GNGH / Cadmium; 2P299V784P / Lead; 7440-31-5 / Tin; 789U1901C5 / Copper; 81AH48963U / Molybdenum; 9IT35J3UV3 / Antimony; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; N712M78A8G / Arsenic; OW5102UV6N / Beryllium
  •  go-up   go-down


19. Olowu WA, Adelusola KA: Stage 2 hypertension in a child with a rapidly enlarging kidney: question. Burkitt's lymphoma. Pediatr Nephrol; 2008 May;23(5):727-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage 2 hypertension in a child with a rapidly enlarging kidney: question. Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Hypertension / etiology. Kidney Neoplasms / complications
  • [MeSH-minor] Blood Pressure. Child. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Male. Severity of Illness Index. Time Factors


20. Ozdemir B, Ozcan G, Karaduman B, Teoman AI, Ayhan E, Ozer N, Us D: Lactoferrin in Gingival Crevicular Fluid and Peripheral Blood during Experimental Gingivitis. Eur J Dent; 2009 Jan;3(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine alterations of GCF and blood levels of LF (LF-GCF and LF-BL, respectively), employing the experimental gingivitis model.
  • LF-BL appeared to follow the same pattern.
  • Significant negative correlation was detected between the level of LF-BL and BOP at day 14 (P<.05), whereas significant positive correlation was noticed between LF-BL and clinical scores PI, GI and BOP at day 35 (P<.05).
  • CONCLUSIONS: LF-BL followed the same pattern with LF-GCF and clinical scores during the experimental gingivitis and recovery periods, although alterations of the LF-BL appeared statistically insignificant.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Periodontal Res. 2006 Jun;41(3):184-8 [16677286.001]
  • [Cites] J Clin Periodontol. 2000 May;27(5):366-9 [10847542.001]
  • [Cites] Acta Odontol Scand. 1963 Dec;21:533-51 [14121956.001]
  • [Cites] Acta Odontol Scand. 1964 Feb;22:121-35 [14158464.001]
  • [Cites] J Clin Periodontol. 1999 Jul;26(7):453-60 [10412850.001]
  • [Cites] J Clin Periodontol. 1998 Sep;25(9):695-700 [9763323.001]
  • [Cites] J Clin Immunol. 1998 Jul;18(4):291-8 [9710746.001]
  • [Cites] J Clin Periodontol. 1998 Aug;25(8):677-86 [9722273.001]
  • [Cites] Aust Dent J. 1998 Feb;43(1):40-4 [9583225.001]
  • [Cites] Oral Dis. 1996 Jun;2(2):129-34 [8957925.001]
  • [Cites] J Clin Periodontol. 1996 Mar;23(3 Pt 1):160-4 [8707973.001]
  • [Cites] J Clin Periodontol. 1995 Dec;22(12):946-52 [8613564.001]
  • [Cites] Clin Diagn Lab Immunol. 1995 Nov;2(6):763-5 [8574844.001]
  • [Cites] J Periodontal Res. 1994 Jul;29(4):276-82 [7932021.001]
  • [Cites] J Periodontal Res. 1994 May;29(3):196-202 [7515961.001]
  • [Cites] J Leukoc Biol. 1993 May;53(5):591-7 [8501397.001]
  • [Cites] J Clin Periodontol. 1993 Sep;20(8):578-83 [8408719.001]
  • [Cites] Scott Med J. 1993 Jun;38(3):73-4 [8356427.001]
  • [Cites] J Clin Periodontol. 1993 Jan;20(1):26-31 [8421112.001]
  • [Cites] J Dent Res. 1992 Feb;71(2):359-63 [1372921.001]
  • [Cites] J Periodontol. 1987 Aug;58(8):529-39 [3305856.001]
  • [Cites] Scand J Infect Dis. 1989;21(6):709-15 [2694351.001]
  • [Cites] Clin Exp Immunol. 1988 Jan;71(1):132-7 [3280178.001]
  • [Cites] J Immunol. 1980 Feb;124(2):855-62 [6153206.001]
  • [Cites] J Periodontol. 1983 Aug;54(8):481-7 [6578319.001]
  • [Cites] J Immunol. 1979 Jul;123(1):285-94 [448150.001]
  • [Cites] Helv Odontol Acta. 1971 Oct;15(2):107-13 [5315729.001]
  • [Cites] Infect Immun. 1976 May;13(5):1347-53 [1270143.001]
  • [Cites] J Clin Periodontol. 2004 Nov;31(11):945-50 [15491308.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):728-31 [15329381.001]
  • [Cites] J Periodontal Res. 2004 Oct;39(5):287-93 [15324348.001]
  • [Cites] J Clin Periodontol. 2004 Jul;31(7):511-4 [15191585.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):917-28 [15149504.001]
  • [Cites] J Dent Res. 2001 Nov;80(11):2011-5 [11759012.001]
  • [Cites] Acta Physiol Hung. 2000;87(4):329-37 [11732887.001]
  • [Cites] J Periodontol. 2001 Jul;72(7):883-8 [11495136.001]
  • [Cites] J Periodontol. 2001 Feb;72(2):146-51 [11288786.001]
  • [Cites] Andrologia. 2005 Oct;37(5):188-94 [16266398.001]
  • (PMID = 19262727.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2647955
  • [Keywords] NOTNLM ; Gingival crevicular fluid / Gingivitis / Lactoferrin / Periodontal index / Peripheral blood
  •  go-up   go-down


21. Kipnis E, Desoutter E, Dalmas S, Marciniak B: Total spinal anesthesia during combined general-epidural anesthesia in a 7-year-old child. Paediatr Anaesth; 2005 Jan;15(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent previous lumbar punctures and intrathecal chemotherapy for Burkitt's lymphoma at the same level may have facilitated dural breach.
  • [MeSH-minor] Abdomen / surgery. Antineoplastic Agents / adverse effects. Burkitt Lymphoma / complications. Burkitt Lymphoma / surgery. Child. Female. Hemodynamics / physiology. Humans. Medical Errors. Monitoring, Intraoperative

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649165.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The differentiation of benign versus malignant hematologic processes on cerebrospinal fluid (CSF) is difficult given the significant morphologic overlap and frequently scant specimen.
  • We identified 32 cases of CSF submitted for cytopathologic analysis with corresponding FC data, histologic, or clinical follow-up.
  • These diagnoses were compared with the original diagnoses made in the context of clinical information and ancillary studies.
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • Interestingly, the correct diagnoses were rendered in 73% of benign cases, compared with 52% of malignant cases.
  • Of the malignant cases, there was a higher proportion of correct diagnosis based on morphology in the acute malignancies (67%) versus the chronic malignancies (47%).
  • Features most useful for diagnosis of malignancy included cellular monotony and nuclear contour irregularity.
  • The diagnosis of malignancy based on morphology alone is difficult in CSF.
  • Ancillary studies such as FC analyses greatly enhance the ability to accurately distinguish between benign and malignant hematologic processes.
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Behler CM, Kaplan LD: Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol; 2006 Sep;18(5):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of HIV-related non-Hodgkin lymphoma.
  • PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of non-Hodgkin lymphoma.
  • Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated non-Hodgkin lymphoma remains an important problem.
  • RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-non-Hodgkin lymphoma.
  • Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or refractory HIV-non-Hodgkin lymphoma.
  • New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-non-Hodgkin lymphoma have also recently been reported.
  • SUMMARY: Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.
  • For aggressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.
  • HIV-associated Burkitt lymphoma should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.
  • Autologous stem cell transplantation should be considered for selected patients with relapsed or refractory HIV-non-Hodgkin lymphoma.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894290.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 65
  •  go-up   go-down


24. Shim GJ, Gherman D, Kim HJ, Omoto Y, Iwase H, Bouton D, Kis LL, Andersson CT, Warner M, Gustafsson JA: Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol; 2006 Feb;208(3):408-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of oestrogen receptors in human secondary lymphoid tissues.
  • To determine whether these contradictory effects of oestrogen relate to the involvement of distinct effects of the two ERs, we investigated expression of ERalpha and ERbeta in human secondary lymphoid tissues.
  • In addition, in different human lymphoma cell lines including Hodgkin lymphoma, Burkitt lymphoma, and multiple myeloma, ERbeta is abundant while ERalpha is not detectable.
  • Our results indicate that ERbeta is the predominant type of ER in mature lymphocytes.
  • We suggest that ERalpha and ERbeta have distinct roles in secondary lymphoid tissues and that further studies with ERbeta-specific agonists will help to elucidate the role of ERbeta in these tissues.
  • [MeSH-major] Autoimmune Diseases / metabolism. Lymphoid Tissue / chemistry. Receptors, Estrogen / analysis
  • [MeSH-minor] Adult. Blotting, Western / methods. Breast Neoplasms / immunology. Burkitt Lymphoma / chemistry. Cell Line. Cell Line, Tumor. Child, Preschool. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Female. Hodgkin Disease / metabolism. Humans. Leukocytes / chemistry. Leukocytes, Mononuclear / chemistry. Male. Palatine Tonsil / chemistry. Spleen / chemistry

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294372.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Receptors, Estrogen
  •  go-up   go-down


25. Coca A, Williams WJ, Roberge RJ, Powell JB: Effects of fire fighter protective ensembles on mobility and performance. Appl Ergon; 2010 Jul;41(4):636-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study consisted of measuring a battery of motions and fire fighter specific tasks while wearing a standard fire fighter ensemble (SE) or regular light clothing (baseline or BL).
  • Several BL ROM tests were significantly (p < 0.05) different from the SE test, including a decrease in shoulder flexion, cervical rotation and flexion, trunk lateral flexion, and stand and reach.
  • The development of a Standard Ergonomics Test Practice for further use in laboratories that conduct personal protective systems evaluations using human test subjects is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • (PMID = 20153458.001).
  • [ISSN] 1872-9126
  • [Journal-full-title] Applied ergonomics
  • [ISO-abbreviation] Appl Ergon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol; 2010 Jun;28(2):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
  • Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene.
  • The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL).
  • While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic and cytogenetics intermediate between DLBCL and BL, and cannot be classified with certainty in these categories.
  • Distinguishing between BL and DLBCL is critical, as the two diseases require different management.
  • This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma', now listed in the updated WHO classification.
  • [MeSH-major] B-Lymphocytes / pathology. Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Biopsy. Child. Diagnosis, Differential. Disease Management. Gene Expression Profiling. Genes, Immunoglobulin. Genes, bcl-2. Genes, myc. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Translocation, Genetic

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19844983.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


27. Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, Bornkamm GW: C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer; 2007 Apr 1;120(7):1387-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
  • Deregulation of the proto-oncogene c-myc is a key event in the pathogenesis of many tumors.
  • A paradigm is the activation of the c-myc gene by chromosomal translocations in Burkitt lymphoma (BL).
  • Despite expression of a restricted set of Epstein-Barr viral (EBV) antigens, BL cells are not recognized by antigen-specific cytotoxic T cells (CTLs) because of their inability to process and present HLA class I-restricted antigens.
  • In contrast, cells of EBV-driven posttransplant lymphoproliferative disease (PTLD) are recognized and rejected by EBV-specific CTLs.
  • It is not known whether the poor immunogenicity of BL cells is due to nonexpression of viral antigens, overexpression of c-myc, or both.
  • To understand the basis for immune recognition and escape, we have compared the mRNA expression profiles of BL and EBV-immortalized cells (as PTLD model).
  • Among the genes expressed at low level in BL cells, we have identified many genes involved in the NF-kappaB and interferon response that play a pivotal role in antigen presentation and immune recognition.
  • Using a cell line in which EBNA2 and c-myc can be regulated at will, we show that c-MYC negatively regulates STAT1, the central player linking the Type-I and Type-II interferon response.
  • Switching off c-myc expression leads to STAT1 induction through a direct and indirect mechanism involving induction of Type-I interferons. c-MYC thus masks an interferon-inducing activity in these cells.
  • Our findings imply that immune escape of tumor cells is not only a matter of in vivo selection but may be additionally promoted by activation of a cellular oncogene.
  • [MeSH-major] Burkitt Lymphoma / etiology. Gene Expression Regulation, Neoplastic / physiology. Genes, myc / physiology. Interferon-beta / pharmacology. NF-kappa B / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Blotting, Western. Chromatin Immunoprecipitation. Gene Expression Profiling. Humans. Microarray Analysis. Promoter Regions, Genetic. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. STAT1 Transcription Factor / genetics. STAT1 Transcription Factor / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17211884.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 77238-31-4 / Interferon-beta
  •  go-up   go-down


28. Mochida A, Gotoh E, Senpuku H, Harada S, Kitamura R, Takahashi T, Yanagi K: Telomere size and telomerase activity in Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cell lines. Arch Virol; 2005 Oct;150(10):2139-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere size and telomerase activity in Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cell lines.
  • The telomere repeat lengths of BL cell lines were quantified by measuring terminal restriction fragment (TRF).
  • Epstein-Barr virus (EBV)-positive Namalwa, Raji, and EB-3 cell lines have long telomeres, i.e.
  • TRFs 10-19 kbp, whereas the Daudi cell line, producing a transformation-defective EBV mutant, has TRFs approximately 2.2 kbp.
  • EBV-negative BJAB and DG75 cell lines have short TRFs 3.9-5.4 kbp, shorter than the approximately 12 kbp TRFs in PBLs.
  • Telomerase activities of these BL cell lines are similar.
  • TRFs of non-BL lymphoma cell lines are 2.3-5.5 kbp.
  • Fluorescent in situ hybridization (FISH) studies of these cell lines showed remarkable heterogeneity of telomere size in chromosomes in the same BL cell.
  • These results suggest that EBV-positive and EBV-negative BL cell lines have experienced various telomere dynamics.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / virology. Herpesvirus 4, Human / isolation & purification. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA, Neoplasm / genetics. Humans. In Situ Hybridization, Fluorescence. Mutation

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986178.001).
  • [ISSN] 0304-8608
  • [Journal-full-title] Archives of virology
  • [ISO-abbreviation] Arch. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


29. Lahiri S, Roy A, Baby SM, Hoshi T, Semenza GL, Prabhakar NR: Oxygen sensing in the body. Prog Biophys Mol Biol; 2006 Jul;91(3):249-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review is divided into three parts: (a) The primary site of oxygen sensing is the carotid body which instantaneously respond to hypoxia without involving new protein synthesis, and is historically known as the first oxygen sensor and is therefore placed in the first section (Lahiri, Roy, Baby and Hoshi).
  • The carotid body senses oxygen in acute hypoxia, and produces appropriate responses such as increases in breathing, replenishing oxygen from air.
  • This response is seen in afferent nerves which are connected synaptically to type I or glomus cells of the carotid body.
  • This inhibition results in membrane K(+) current suppression which is followed by cell depolarization.
  • [MeSH-minor] Animals. Anoxia / metabolism. Carbon Monoxide / metabolism. Carotid Body / metabolism. Cell Membrane / metabolism. Humans. Hypoxia-Inducible Factor 1 / metabolism. Mitochondria / metabolism. Models, Biological. Neurotransmitter Agents / metabolism. Nitric Oxide / metabolism. Potassium Channels / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. Carbon monoxide .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137743.001).
  • [ISSN] 0079-6107
  • [Journal-full-title] Progress in biophysics and molecular biology
  • [ISO-abbreviation] Prog. Biophys. Mol. Biol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R-37-HL43413; United States / NIGMS NIH HHS / GM / R01 GM57654; United States / NHLBI NIH HHS / HL / R01-HL50180
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1; 0 / Neurotransmitter Agents; 0 / Potassium Channels; 31C4KY9ESH / Nitric Oxide; 7U1EE4V452 / Carbon Monoxide; S88TT14065 / Oxygen
  • [Number-of-references] 250
  •  go-up   go-down


30. Soresi M, Giannitrapani L, Florena AM, La Spada E, Di Gesaro V, Rappa F, Alessandri A, Tripi S, Romano M, Montalto G: Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol; 2009 Dec;64(12):1181-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the reliability of the bright liver (BL) echo pattern on ultrasound to detect histological steatosis in chronic cryptogenic hypertransaminasaemia (CCH) and hepatitis C virus (HCV)-related forms of hypertransaminasaemia.
  • The reliability of the BL sign was estimated using the sensitivity, specificity, positive and negative predictive values.
  • In a multivariate analysis, the variable associated with the BL echo pattern was steatosis percentage (p=0.0018).
  • The sensitivity of the BL echo pattern was 88% in the CCH group [confidence interval (CI) 95% 74-95] versus 61% (CI 95% 44-73) in the HCV genotype 1/2 group.
  • CONCLUSION: In CCH the BL echo pattern has excellent reliability in diagnosing steatosis, better than in HCV hypertransaminasaemia because of the higher prevalence and extent of steatosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Radiol. 2009 Dec;64(12):1188-9 [19913128.001]
  • (PMID = 19913127.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.6.1.- / Transaminases
  •  go-up   go-down


31. Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganapati R: The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT. Lepr Rev; 2010 Mar;81(1):41-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: From a cohort of 400 untreated MB patients, a comparable group of 100 each receiving MDT + steroids (group A) vs MDT alone (group B) were assessed at 18 months as compared to month zero with respect to clinical and granuloma regression, M. leprae killing and clearance, and nerve functions.
  • Multiplication of M. leprae in the mouse foot pad (MFP) indicating the presence of viable bacilli was seen in 14% and 16% of SSS positive BL-LLs patients in groups A and B respectively (P not significant).
  • Using clinical tests (nerve palpation, monofilament and voluntary muscle testing), the proportion of sensory and motor nerves showing improvement or deterioration were similar in the two groups.
  • However the continued presence of viable bacteria in > 14% of BL-LLs patients indicate that 12 months of MDT may be insufficient for complete bacterial killing.
  • A better immuno-modulatory drug or a modified corticosteroid regime is needed.

  • Genetic Alliance. consumer health - Leprosy 3.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496569.001).
  • [ISSN] 0305-7518
  • [Journal-full-title] Leprosy review
  • [ISO-abbreviation] Lepr Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Leprostatic Agents
  •  go-up   go-down


32. Zhang P, Sun Q, Turner CH, Yokota H: Knee loading accelerates bone healing in mice. J Bone Miner Res; 2007 Dec;22(12):1979-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knee loading has been shown to induce anabolic responses to murine tibias and femora when a strain of 10-20 mustrain is applied at the site of new bone formation.
  • MATERIAL AND METHODS: Fifty-three C57/BL/6 female mice were used.
  • Last, bone histomorphometry revealed that bone formation was stimulated from the site proximal (close to the knee) to the wound.
  • CONCLUSIONS: The reparative and remodeling phases of wound healing were enhanced by loads applied to the knee without inducing significant in situ strain at the site of wounds.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2003 Aug;85-A(8):1446-53 [12925623.001]
  • [Cites] Calcif Tissue Int. 2003 Apr;72(4):498-504 [12522665.001]
  • [Cites] J Orthop Res. 2003 Nov;21(6):1011-7 [14554213.001]
  • [Cites] Bone. 2003 Dec;33(6):960-9 [14678856.001]
  • [Cites] Med Eng Phys. 2004 Jul;26(6):493-501 [15234685.001]
  • [Cites] J Orthop Res. 2004 Sep;22(5):1079-85 [15304282.001]
  • [Cites] J Orthop Res. 1984;1(4):431-49 [6491792.001]
  • [Cites] J Bone Joint Surg Br. 1985 Aug;67(4):650-5 [4030869.001]
  • [Cites] J Orthop Res. 1987;5(1):29-35 [3819909.001]
  • [Cites] Clin Orthop Relat Res. 1989 Apr;(241):36-47 [2924478.001]
  • [Cites] J Bone Joint Surg Br. 1991 Jul;73(4):654-9 [2071654.001]
  • [Cites] Clin Orthop Relat Res. 1994 Apr;(301):281-90 [8156689.001]
  • [Cites] J Orthop Res. 1996 Jan;14(1):80-4 [8618171.001]
  • [Cites] J Bone Joint Surg Am. 1998 Jun;80(6):868-78 [9655105.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S105-15 [9917631.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S132-47 [9917634.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S163-78 [9917637.001]
  • [Cites] J Bone Joint Surg Am. 1955 Oct;37-A(5):1035-68 [13263349.001]
  • [Cites] Osteoporos Int. 2005 Mar;16 Suppl 2:S36-43 [15372141.001]
  • [Cites] J Bone Miner Metab. 2005;23(4):302-8 [15981026.001]
  • [Cites] J Orthop Res. 2005 Sep;23(5):1022-8 [15878254.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76 [16269906.001]
  • [Cites] J Appl Physiol (1985). 2006 May;100(5):1452-9 [16410382.001]
  • [Cites] J Appl Physiol (1985). 2006 May;100(5):1441-2 [16614362.001]
  • [Cites] J Orthop Res. 2006 Aug;24(8):1679-86 [16788988.001]
  • [Cites] Ann Biomed Eng. 2006 Oct;34(10):1600-6 [17029032.001]
  • [Cites] Bone. 2007 Feb;40(2):538-43 [17070127.001]
  • [Cites] Bone. 2007 May;40(5):1320-8 [17344109.001]
  • [Cites] J Orthop Trauma. 2001 Jan;15(1):54-60 [11147689.001]
  • [Cites] J Bone Joint Surg Br. 2001 Mar;83(2):157-64 [11284556.001]
  • [Cites] Clin Orthop Relat Res. 2001 Apr;(385):192-8 [11302314.001]
  • [Cites] Bone. 2001 Apr;28(4):423-9 [11336924.001]
  • [Cites] J Orthop Sci. 2001;6(6):571-5 [11793181.001]
  • [Cites] Osteoporos Int. 2002 Sep;13(9):688-700 [12195532.001]
  • [Cites] J Orthop Res. 2002 Sep;20(5):1099-105 [12382978.001]
  • [Cites] Calcif Tissue Int. 2003 Jul;73(1):49-55 [14506954.001]
  • (PMID = 17696761.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R03 AG024596; United States / NIA NIH HHS / AG / AG024596; United States / NIAMS NIH HHS / AR / R01 AR052144-06; United States / NIAMS NIH HHS / AR / AR052144-06; United States / NIAMS NIH HHS / AR / R01 AR052144; United States / NIAMS NIH HHS / AR / AR52144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217624; NLM/ PMC2907257
  •  go-up   go-down


33. Sen I, Kumar S, Bhardwaj N, Wig J: A left paraglossal approach for oral intubation in children scheduled for bilateral orofacial cleft reconstruction surgery--a prospective observational study. Paediatr Anaesth; 2009 Feb;19(2):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the feasibility of left paraglossal laryngoscopy as a primary technique for airway management in these children.
  • METHODS: After institutional ethical committee approval and informed consent, we enrolled 21 children with uncorrected bilateral lip and palate deformities (BL CL/P).
  • Endotracheal intubation was performed with Miller's straight blade laryngoscope, introduced using left paraglossal approach.
  • CONCLUSION: Keeping in mind midline tissue support loss in cleft deformities, we propose routine use of left paraglossal laryngoscopic approach for intubating children with uncorrected BL CL/P anomalies.

  • MedlinePlus Health Information. consumer health - Cleft Lip and Palate.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Paediatr Anaesth. 2009 Jun;19(6):645-6 [19646003.001]
  • (PMID = 19207900.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Seipel D, Ribeiro-Gomes FL, Barcelos MW, Ramalho AV, Kanashiro MM, Kipnis TL, Arnholdt AC: Monocytes/macrophages infected with Toxoplasma gondii do not increase co-stimulatory molecules while maintaining their migratory ability. APMIS; 2009 Sep;117(9):672-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the ability of infected macrophages from wild type C57/BL/6 or CD14(-/-) mice to migrate in 8 mum transwells.
  • Infected cells from CD14(-/-) mice were more likely to de-adhere than infected cells from wild type mice but they did not show any increase in migratory ability.
  • The non-stimulatory profile of these infected cells may contribute to parasite spread throughout the lymphatic circulation in the initial phases of infection.
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antigens, CD14 / genetics. Antigens, CD14 / metabolism. Cell Adhesion Molecules / metabolism. Cell Line. Cell Movement. HLA-DR Antigens / metabolism. Humans. In Vitro Techniques. Macrophage Activation. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Knockout

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703127.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Cell Adhesion Molecules; 0 / HLA-DR Antigens
  •  go-up   go-down


35. Isenhath SN, Fukano Y, Usui ML, Underwood RA, Irvin CA, Marshall AJ, Hauch KD, Ratner BD, Fleckman P, Olerud JE: A mouse model to evaluate the interface between skin and a percutaneous device. J Biomed Mater Res A; 2007 Dec 15;83(4):915-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Percutaneous medical devices are integral in the management and treatment of disease.
  • Porous poly(2-hydroxyethyl methacrylate) [poly(HEMA)] rods were implanted for 7 days in the dorsal skin of C57 BL/6 mice.
  • This in vivo model permits examination of the implant/skin interface and will be useful for future studies designed to facilitate skin cell attachment where percutaneous devices penetrate the skin.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2007.
  • (PMID = 17567856.001).
  • [ISSN] 1549-3296
  • [Journal-full-title] Journal of biomedical materials research. Part A
  • [ISO-abbreviation] J Biomed Mater Res A
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK59221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biocompatible Materials; 25249-16-5 / Polyhydroxyethyl Methacrylate
  •  go-up   go-down


36. Bruge F, Virgili S, Cacciamani T, Principi F, Tiano L, Littarru GP: NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt's lymphoma cell lines. Biofactors; 2008;32(1-4):71-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt's lymphoma cell lines.
  • In fact, low level of NQO1 activity is often associated with increased risk of developing different types of tumours and with toxic effects linked to environmental quinones.
  • In a previous report we analyzed the relationship between the oxidative stress induced by UV radiation and CoQ10 content in Burkitt's lymphoma cell lines compared to HL-60.
  • In the present work, in order to inquire if NQO1 plays a role in the CoQ reducing capacity observed in the lymphoblastoid cell lines, we analyzed the transcription and translation products of this gene in Raji and Daudi cells, compared to cell lines possessing low and high NQO1 activity.
  • Therefore in Burkitt's lymphoma cell lines the NQO1 gene is not efficiently translated and this effect is not related to (C609T) polymorphism.
  • Further studies will be necessary to find the enzyme responsible for CoQ10 reducing activity observed in lymphoma cell lines.
  • On the other hand, this result suggests a careful re-evaluation of data concerning loss of NQO1 activity and polymorphisms in tumour cells.
  • [MeSH-major] Burkitt Lymphoma / enzymology. NAD(P)H Dehydrogenase (Quinone) / genetics
  • [MeSH-minor] Alternative Splicing. Cell Line, Tumor. HL-60 Cells / enzymology. Humans. K562 Cells. Polymorphism, Genetic. RNA, Messenger / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096102.001).
  • [ISSN] 0951-6433
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


37. Fleta Asín B, Gonzalvo Liarte MC, Palomera Bernal L: [Abdominal Burkitt lymphoma in an adolescent]. An Med Interna; 2006 Nov;23(11):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal Burkitt lymphoma in an adolescent].
  • [Transliterated title] Linfoma de Burkitt abdominal en un adolescente.
  • We report the case of a male adolescent affected by Burkitt Lymphoma which presented as acute abdominal pain and rapid growth mass.
  • We consider some other causes of abdominal bulky in childhood, especially primary tumours and non tumoural diseases.
  • [MeSH-major] Abdominal Pain / etiology. Burkitt Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222072.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Brekalo Z, Kvesić A, Galić G, Kukić-Brusić S, Martinović V, Jonovska S: Burkitt's lymphoma in the boy: infiltration in the stomach, colon and the retroperitoneum--ileocecal invagination. Coll Antropol; 2007 Dec;31(4):1183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in the boy: infiltration in the stomach, colon and the retroperitoneum--ileocecal invagination.
  • A resection of the small intestine and a ileocolic anastomosis was performed.
  • The pathohistological test shows the primar abdominal Burkitt's lymphoma.
  • We, herewith, suggest at the importance of the echography analysis when diagnosing the Burkitt's tumor and give advantage to this analysis against the computerized tomography.
  • We also point at the huge level of malignancy of the Burkitt's tumor in this boy.
  • [MeSH-major] Burkitt Lymphoma / pathology. Colonic Neoplasms / pathology. Ileocecal Valve. Intussusception / etiology. Retroperitoneal Neoplasms / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217479.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


39. Tallman MS, Zakarija A: Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease. Transfus Apher Sci; 2005 Feb;32(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
  • Since its initial description approximately 50 years ago, there has been an impressive evolution in therapies for hairy cell leukemia.
  • Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A immunoconjugate, BL-22.
  • [MeSH-major] Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / mortality
  • [MeSH-minor] ADP Ribose Transferases / chemistry. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Antineoplastic Agents / therapeutic use. Bacterial Toxins / chemistry. Cell Adhesion Molecules / biosynthesis. Cladribine / therapeutic use. Clinical Trials as Topic. Exotoxins / chemistry. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Lectins / biosynthesis. Pentostatin / therapeutic use. Recurrence. Remission Induction. Rituximab. Sialic Acid Binding Ig-like Lectin 2. Time Factors. Treatment Outcome. Virulence Factors / chemistry

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737878.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Exotoxins; 0 / Immunosuppressive Agents; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Virulence Factors; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  • [Number-of-references] 40
  •  go-up   go-down


40. Kirchherr JL, Lu X, Kasongo W, Chalwe V, Mwananyanda L, Musonda RM, Xia SM, Scearce RM, Liao HX, Montefiori DC, Haynes BF, Gao F: High throughput functional analysis of HIV-1 env genes without cloning. J Virol Methods; 2007 Jul;143(1):104-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Functional human immunodeficiency virus type 1 (HIV-1) env genes have been widely used for vaccine design, neutralization assays, and pathogenesis studies.
  • After infecting TZM-bl cells, 75 out of 87 (86%) of the rev/env gene cassettes were functional.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1989 Aug 17;340(6234):571-4 [2475780.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2019-22 [15044802.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Virol. 1994 Dec;68(12):8380-5 [7966630.001]
  • [Cites] J Virol. 1995 Sep;69(9):5217-27 [7636963.001]
  • [Cites] J Virol. 1990 May;64(5):2416-20 [2325207.001]
  • [Cites] J Virol. 1990 Dec;64(12):5840-50 [2243378.001]
  • [Cites] J Virol. 1994 Dec;68(12):7689-96 [7966558.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):307-12 [12646921.001]
  • [Cites] J Virol. 2006 Dec;80(23):11776-90 [16971434.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):344-8 [16327776.001]
  • [Cites] J Virol. 2005 Aug;79(16):10108-25 [16051804.001]
  • [Cites] J Virol. 2005 Feb;79(4):2097-107 [15681412.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):406-13 [15635002.001]
  • [Cites] J Virol. 1996 Mar;70(3):1651-67 [8627686.001]
  • [Cites] J Virol Methods. 1998 Dec;76(1-2):139-48 [9923748.001]
  • [Cites] Science. 1996 Jul 26;273(5274):415-6 [8677432.001]
  • [Cites] Virology. 1999 Jul 5;259(2):324-33 [10388657.001]
  • (PMID = 17416428.001).
  • [ISSN] 0166-0934
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007392; United States / NIAID NIH HHS / AI / P30 AI64518; United States / NIAID NIH HHS / AI / AI064518-02; United States / NIAID NIH HHS / AI / T32 AI007392-17; United States / NIAID NIH HHS / AI / AI007392-17; United States / NIAID NIH HHS / AI / U01 AI067854; United States / NIAID NIH HHS / AI / AI055386; United States / NIAID NIH HHS / AI / R03 AI54155; United States / NIAID NIH HHS / AI / 5T32 AI007392; United States / NIAID NIH HHS / AI / R03 AI054155; United States / NIAID NIH HHS / AI / P30 AI064518-02; United States / NIAID NIH HHS / AI / U19 AI067854; United States / NIAID NIH HHS / AI / R21 AI055386; United States / NIAID NIH HHS / AI / R03 AI054155-02; United States / NIAID NIH HHS / AI / AI067854-02; United States / NIAID NIH HHS / AI / AI054155-02; United States / NIAID NIH HHS / AI / P30 AI064518; United States / NIAID NIH HHS / AI / AI055386-02; United States / NIAID NIH HHS / AI / R21 AI055386-02; United States / NIAID NIH HHS / AI / U19 AI067854-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Gene Products, env
  • [Other-IDs] NLM/ NIHMS25360; NLM/ PMC1948023
  •  go-up   go-down


41. Lutz NW, Franks SE, Frank MH, Pomer S, Hull WE: Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays. MAGMA; 2005 Jul;18(3):144-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.
  • KTCTL-26 and KTCTL-2 are renal cell carcinoma (RCC) lines with high and low expression of P-170 glycoprotein, respectively.
  • Inherent differences between the two cell lines in terms of phosphate metabolites and growth characteristics in culture were examined for possible association with multidrug resistance (MDR).
  • KTCTL-26 cells were more sensitive than KTCTL-2 to 0.011 mircroM VBL alone (87% vs. 102% survival) or to 0.011 microM BL + 10 microM DIL (55% vs. 80% survival).
  • Metabolomic 31P MRS detects different metabolite profiles for RCC cell lines with different MDR phenotypes and may be useful for noninvasive characterization of tumors in a clinical setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / pathology. Cell Proliferation / drug effects. Cell Survival / drug effects. Kidney Neoplasms / pathology. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Cell Line, Tumor. Diltiazem / administration & dosage. Dose-Response Relationship, Drug. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Humans. Interferon-alpha / administration & dosage. Phosphates / analysis. Phosphorus Isotopes. Treatment Outcome. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. DILTIAZEM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Nov 1;87(3):507-17 [8898203.001]
  • [Cites] Oncol Res. 1998;10 (3):123-32 [9700723.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):312-6 [7678345.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 21;81(12):907-10 [2567355.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8 [9272126.001]
  • [Cites] Anticancer Drugs. 1998 Jun;9(5):449-56 [9660543.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4087-90 [3731076.001]
  • [Cites] Biochem Soc Trans. 1997 Aug;25(3):1088-96 [9388605.001]
  • [Cites] Lipids. 1999;34 Suppl:S57-63 [10419089.001]
  • [Cites] Ann Intern Med. 1982 May;96(5):549-56 [6176159.001]
  • [Cites] Biochem Pharmacol. 2000 Nov 1;60(9):1381-90 [11008132.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7512-23 [14576855.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(10):546-54 [9393588.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1463-6 [10365124.001]
  • [Cites] NMR Biomed. 2000 Apr;13(2):92-101 [10797637.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1384-91 [8912533.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9 [9272128.001]
  • [Cites] NMR Biomed. 1993 Jul-Aug;6(4):254-63 [8217527.001]
  • [Cites] Urologe A. 2002 May;41(3):282-7 [12132280.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Feb;106(2):169-72 [7819747.001]
  • [Cites] NMR Biomed. 1999 Jun;12(4):217-20 [10421913.001]
  • [Cites] Eur Urol. 1990;17(1):72-5 [1969346.001]
  • [Cites] J Urol. 1990 Sep;144(3):755-9 [1974934.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3396-401 [3581077.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1633-7 [2576349.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(2):117-20 [10190320.001]
  • [Cites] Breast Cancer Res Treat. 1997 Mar;43(1):15-25 [9065595.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5440-6 [3416301.001]
  • [Cites] NMR Biomed. 1994 Jun;7(4):172-80 [7946995.001]
  • [Cites] Trends Biochem Sci. 1992 Jan;17(1):18-21 [1374941.001]
  • [Cites] Magn Reson Med. 1993 Jan;29(1):113-8 [8419730.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1545-8 [10365142.001]
  • [Cites] Annu Rev Med. 1991;42:277-86 [2035973.001]
  • [Cites] Int Urol Nephrol. 2003;35(1):15-7 [14620276.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):226-33 [1449961.001]
  • [Cites] NMR Biomed. 1990 Apr;3(2):78-89 [2390457.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23 ):6937-47 [11389609.001]
  • [Cites] Orv Hetil. 1997 Jan 12;138(2):67-70 [9064618.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2952-8 [7910518.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):367-71 [11445853.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 30;1531(1-2):111-31 [11278177.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4190-4 [2364374.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 21;81(12):910-3 [2567356.001]
  • [Cites] Urol Res. 1993 Mar;21(2):79-81 [8099243.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3461-7 [8758912.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):121-8 [12017273.001]
  • [Cites] J Urol. 1988 Apr;139(4):862-5 [3352061.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1365-74 [8694503.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):303-24 [1333263.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3161-6 [11848468.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Sep;20(3):393-400 [11718220.001]
  • [Cites] J Chemother. 1994 Oct;6(5):337-42 [7861198.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):3915-9 [11911269.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49911-20 [12297506.001]
  • [Cites] Urol Res. 1990;18(5):309-12 [1979457.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):11-7 [9240173.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):94-104 [7707396.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1541-3 [10365141.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] J Pharm Pharmacol. 2000 Mar;52(3):289-96 [10757416.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):347-57 [11238696.001]
  • [Cites] Cancer Treat Rep. 1986 Sep;70(9):1081-4 [3091246.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1452-5 [2924298.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4 [3368466.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):905-8 [8102519.001]
  • [Cites] Med Oncol. 2001;18(3):189-95 [11917943.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):485-93 [1911189.001]
  • [Cites] Mol Pharmacol. 1999 Nov;56(5):997-1004 [10531406.001]
  • [Cites] Cancer Res. 1991 Mar 15;51(6):1638-44 [1998955.001]
  • (PMID = 15977034.001).
  • [ISSN] 0968-5243
  • [Journal-full-title] Magma (New York, N.Y.)
  • [ISO-abbreviation] MAGMA
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI050783; United States / NIAID NIH HHS / AI / K08 AI050783-03; United States / NCI NIH HHS / CA / R01 CA113796; United States / NCI NIH HHS / CA / R01 CA113796-01A1
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Phosphates; 0 / Phosphorus Isotopes; 5V9KLZ54CY / Vinblastine; EE92BBP03H / Diltiazem
  •  go-up   go-down


42. Cardini F, Lombardo P, Regalia AL, Regaldo G, Zanini A, Negri MG, Panepuccia L, Todros T: A randomised controlled trial of moxibustion for breech presentation. BJOG; 2005 Jun;112(6):743-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the efficacy of moxibustion for the correction of fetal breech presentation in a non-Chinese population.
  • SAMPLE: Healthy non-Chinese nulliparous pregnant women at 32-33 weeks + 3 days of gestational age with the fetus in breech presentation.
  • Treatment consisted of moxibustion (stimulation with heat from a stick of Artemisia vulgaris) at the BL 67 acupuncture point (Zhiyin) for one or two weeks.
  • CONCLUSIONS: The results underline the methodological problems evaluating of a traditional treatment transferred from a different cultural context.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924530.001).
  • [ISSN] 1470-0328
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Nomura T, Ueno M, Yamada Y, Takatsuto S, Takeuchi Y, Yokota T: Roles of brassinosteroids and related mRNAs in pea seed growth and germination. Plant Physiol; 2007 Apr;143(4):1680-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When seeds were rapidly growing, the level of biologically active BRs (brassinolide [BL] and castasterone [CS]) and the transcript levels of two BR C-6 oxidases (CYP85A1 and CYP85A6) reached a maximum, suggesting the significance of BL and CS in seed development.
  • In the early stages of germination, CS, but not BL, appeared and its level increased in the growing tissues in which the transcript level of CYP85A1 and CYP85A6 was high, suggesting the significance of CS in seed germination and early seedling growth of pea.
  • 6-Deoxocathasterone (6-deoxoCT) was the quantitatively major BR in mature seeds.
  • In mature seeds, most of mRNAs were present, but the level was generally lower compared with immature seeds.
  • However, CYP90A9 mRNA rapidly increased during seed development and reached the maximum in mature seeds.
  • The mRNAs stored in mature pea seeds seem to be utilized when seeds germinate.
  • However, it was found that de novo transcription of mRNAs also starts as early as during seed imbibition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15316-23 [10611382.001]
  • [Cites] Plant Physiol. 2003 Dec;133(4):1643-53 [14605216.001]
  • [Cites] Plant Physiol. 2001 Feb;125(2):763-9 [11161033.001]
  • [Cites] Phytochemistry. 2001 May;57(2):171-8 [11382232.001]
  • [Cites] Cell. 2001 Jun 1;105(5):625-36 [11389832.001]
  • [Cites] Plant Physiol. 2001 Jun;126(2):770-9 [11402205.001]
  • [Cites] Plant Mol Biol. 2001 Nov;47(4):491-8 [11669574.001]
  • [Cites] Plant Physiol. 2002 Nov;130(3):1152-61 [12427982.001]
  • [Cites] Plant Physiol. 2004 Aug;135(4):2220-9 [15286289.001]
  • [Cites] Plant Physiol. 2004 Aug;135(4):2196-206 [15299131.001]
  • [Cites] Science. 1996 Apr 19;272(5260):398-401 [8602526.001]
  • [Cites] Cell. 1996 Apr 19;85(2):171-82 [8612270.001]
  • [Cites] Plant Physiol. 1997 Jul;114(3):751-7 [9232866.001]
  • [Cites] Plant Cell. 1998 Feb;10(2):231-43 [9490746.001]
  • [Cites] Plant Physiol. 1998 Dec;118(4):1517-23 [9847128.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17873-9 [15710611.001]
  • [Cites] Plant Cell. 2005 Aug;17(8):2397-412 [16024588.001]
  • [Cites] Ann Bot. 2006 Jan;97(1):65-9 [16303772.001]
  • [Cites] Plant J. 2006 Mar;45(5):765-74 [16460510.001]
  • [Cites] Plant Cell. 2006 Nov;18(11):3275-88 [17138693.001]
  • [Cites] Plant Physiol. 2007 Apr;143(4):1894-904 [17322341.001]
  • [Cites] Phytochemistry. 2001 Dec;58(7):989-94 [11730861.001]
  • [Cites] Plant Physiol. 2002 Sep;130(1):504-13 [12226529.001]
  • [Cites] Plant Physiol. 2002 Oct;130(2):930-9 [12376657.001]
  • [Cites] Plant J. 2002 Nov;32(4):495-508 [12445121.001]
  • [Cites] Annu Rev Plant Biol. 2003;54:137-64 [14502988.001]
  • [Cites] Plant J. 2003 Nov;36(3):291-300 [14617087.001]
  • [Cites] Plant J. 2000 Mar;21(5):431-43 [10758495.001]
  • (PMID = 17322340.001).
  • [ISSN] 0032-0889
  • [Journal-full-title] Plant physiology
  • [ISO-abbreviation] Plant Physiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB218761/ AB218762/ AB218763/ AB218764/ AB277551
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Steroids; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Other-IDs] NLM/ PMC1851827
  •  go-up   go-down


44. Macke C, Prenzler NK, Horn R, Brabant G, Nave H: Ghrelin treatment increases receptor-bound leptin in healthy and endotoxemic obese Lewis rats. Exp Clin Endocrinol Diabetes; 2009 Oct;117(9):473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One crucial factor is the disease-associated disturbed energy balance.
  • Leptin is an adipose-tissue derived peptide, circulating as free (fl) and receptor-bound protein (bl) acting antagonistically to ghrelin's effects on food intake.
  • Blood was collected at five time points (up to 24 h) to measure fl and bl by radioimmunoassay.
  • Results revealed a late shift from high elevated fl to significantly enhanced levels of bl in ghrelin treated obese animals.
  • Both fl and bl levels remained unaffected in lean rats.

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 19876793.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Endotoxins; 0 / Ghrelin; 0 / Leptin; 0 / Receptors, Leptin
  •  go-up   go-down


45. Proquitté H, Elgeti T, Roehr CC, Rogalla P, Wauer RR, Schmalisch G: Comparison of lung volume measurements by multiple-breath heptafluoropropane washout and computed tomography in small ventilated piglets. Med Sci Monit; 2009 Oct;15(10):BR275-280
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of lung volume measurements by multiple-breath heptafluoropropane washout and computed tomography in small ventilated piglets.
  • Tidal volume (V(T)) was measured both by the Dräger Babylog 8000 ventilator (V(T BL)) and the volume difference of the CT scans (V(T CT)).
  • A similar strong correlation without statistically significant bias was found between V(T BL) (8.5+/-2.0 ml) and V(T CT) (9.0+/-2.4 ml) with r=0.91.
  • CONCLUSIONS: Lung volumes measured in small ventilated lungs by HFP washout and CT are highly correlated and independent of body position.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. 1,1,1,2,3,3,3-Heptafluoropropane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789503.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hydrocarbons, Fluorinated; 431-89-0 / HFA 134a
  •  go-up   go-down


46. Takizawa M, Kim JS, Tessarollo L, McNeil N, Waldschmidt TJ, Casellas R, Ried T, Janz S: Genetic reporter system for oncogenic Igh-Myc translocations in mice. Oncogene; 2010 Jul 15;29(28):4113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Myc-deregulating chromosomal T(12;15)(Igh-Myc) translocation, the hallmark mutation of inflammation- and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-associated chromosomal translocations because it is the only translocation in mice that occurs spontaneously (B lymphocyte lineage) and with predictably high incidence (approximately 85% of PCT), and has a direct counterpart in humans: Burkitt lymphoma t(8;14)(q24;q32) translocation.
  • Here, we report on the development of a genetic system for the detection of T(12;15)(Igh-Myc) translocations in plasma cells of a mouse strain in which an enhanced green fluorescent protein (GFP)-encoding reporter gene has been targeted to Myc.
  • GFP expression did not interfere with tumor development or the deregulation of Myc on derivative 12 of translocation, der (12), because the reporter gene was allocated to the reciprocal product of translocation, der (15).
  • Although the described reporter gene approach requires refinement before T(12;15) translocations can be quantitatively detected in vivo, including in B lymphocyte lineage cells that have not yet completed malignant transformation, our findings provide proof of principle that reporter gene tagging of oncogenes in gene-targeted mice can be used to elucidate unresolved questions on the occurrence, distribution and trafficking of cells that have acquired cancer-causing chromosomal translocations of great relevance for humans.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1969 Jun 7;222(5197):994-5 [5789334.001]
  • [Cites] Cell. 2004 Aug 20;118(4):431-8 [15315756.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):232-5 [1729694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7361-5 [8346257.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):419-23 [8542601.001]
  • [Cites] Blood. 1997 Jan 1;89(1):291-6 [8978304.001]
  • [Cites] J Exp Med. 1997 Sep 15;186(6):921-9 [9294146.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;224:251-5 [9308248.001]
  • [Cites] Oncogene. 1997 Nov 6;15(19):2369-77 [9393881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13588-93 [9391070.001]
  • [Cites] Semin Immunol. 2005 Dec;17(6):431-41 [16216522.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):201-14 [16427010.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24 [16815105.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Cytometry A. 2007 Aug;71(8):542-9 [17598185.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1028-38 [19070574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2265-70 [19174520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2717-22 [19196992.001]
  • [Cites] Nature. 2009 Jul 9;460(7252):231-6 [19587764.001]
  • [Cites] Nature. 2009 Dec 10;462(7274):803-7 [20010689.001]
  • [Cites] Nature. 2000 Mar 30;404(6777):510-4 [10761921.001]
  • [Cites] Leukemia. 2000 May;14(5):909-21 [10803525.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1127-35 [10865979.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2023-30 [11511533.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5580-94 [11607811.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1071-7 [12730130.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2842-50 [12743607.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8656-63 [14695177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • (PMID = 20453890.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA151354; United States / NCI NIH HHS / CA / CA151354-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA151354-01; United States / NCI NIH HHS / CA / P50CA097274; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS297327; NLM/ PMC3108853
  •  go-up   go-down


47. Wang XB, Du W, Xia L, Zheng JE, Liu J, He YL, Sun ZM, Huang SA: Cross-lineage expression in 505 patients with acute lymphoblastic leukemia by multiparametric flow cytometry analysis. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1419-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-lineage expression in 505 patients with acute lymphoblastic leukemia by multiparametric flow cytometry analysis.
  • The expression of immunological markers of one hematopoietic lineage on the abnormal cells of another lineage (cross-lineage expression) is a known feature of leukemia.
  • In B-ALL, T-cell antigen CD4, CD5, CD7 and CD2 were found in 27 (6.3%), 12 (2.8%), 8 (1.9%), and 6 (1.4%) cases respectively, and CD7(+), CD2(+) and CD4(+) cases commonly expressed CD13/CD33.
  • In T-ALL, B-cell antigen cCD79a, CD19 and CD22 were found in 6 (8.1%), 5 (6.8%), and 2 (2.8%) cases respectively, and all of CD19(+) and CD22(+) cases were all accompanied with CD13/CD33.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030918.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


48. Vitolo U, Ferreri AJ, Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol; 2008 Feb;65(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • Primary non-Hodgkin's lymphoma of the testis (PTL) accounts for about 9% of testicular neoplasms and 1-2% of all non-Hodgkin's lymphomas.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms; aggressive histologies, especially Burkitt's lymphoma, are prevalent in cases of secondary involvement of testis.
  • The most common clinical presentation is a unilateral painless scrotal swelling, sometimes with sharp scrotal pain or hydrocele.
  • Less frequently, abdominal pain, and ascites can be seen in patients with involvement of retroperitoneal lymph nodes.
  • Although good results with doxorubicin-containing chemotherapy, followed or not by radiotherapy, have been reported, a high proportion of patients with stage I-II diseases experience aggressive relapses, and patients with advanced disease have a very poor prognosis.
  • Orchidectomy followed by R-CHOP combination, with CNS prophylaxis, and prophylactic irradiation of the contralateral testis is the recommended first-line treatment for patients with limited disease.
  • Management of patients with advanced or relapsed disease should follow the worldwide recommendations for nodal DLBCL.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962036.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 40
  •  go-up   go-down


49. Huang JJ, Cheng K, Xie JP, Qin LX: [Discussion on the national standard, the Name and Location of Acupoints]. Zhongguo Zhen Jiu; 2008 Sep;28(9):688-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Location of a part of acupoints in the national standard, The Name and Location of Acupoints, are studied.
  • In combination with anatomy, record of ancient literature and teaching experience, the location of Naohui (TE 13), Chengshan (BL 57), Fengshi (GB 31), Zhongdu (GB 32), Toulinqi (GB 15), Yinbao (LR 9) and Shaoshang (LU 11) in the national standard are analyzed and the relative location methods are raised.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822989.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


50. Su H, Chen YL, Chen SY, Wen B, Yu HS, Hu ZM, Gao JM: [Preparation and bioactivity evaluation of streptavidin-tagged human interleukin-15 fusion protein]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):397-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: pET24a-6His-SA-hIL-15 and pET32a-hIL-15-SA-6His plasmids were constructed and expressed in BL 21(DE3) host bacteria to generate the fusion protein.
  • The recombinant fusion protein IL-15/SA was purified using Ni-NTA affinity chromatography and refolded, and the efficiency of surface modification of the fusion protein on biotinylated cells was examined by fluorescence-activated cell sorting.
  • The purified hIL15-SA fusion protein exhibited a bifunctionality by promoting the proliferation of PBL cells activated by PHA and high-affinity binding to biotinylated cell surface mediated by SA, with a cell surface modification efficiency exceeding 95%.
  • CONCLUSION: SA/hIL-15 bifunctional fusion protein has been successfully obtained to facilitate the future development of hIL-15-surface-modified cancer cell vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304509.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-15; 0 / Recombinant Fusion Proteins; 9013-20-1 / Streptavidin
  •  go-up   go-down


51. Marscher AP, Jorstad SG, D'Arcangelo FD, Smith PS, Williams GG, Larionov VM, Oh H, Olmstead AR, Aller MF, Aller HD, McHardy IM, Lähteenmäki A, Tornikoski M, Valtaoja E, Hagen-Thorn VA, Kopatskaya EN, Gear WK, Tosti G, Kurtanidze O, Nikolashvili M, Sigua L, Miller HR, Ryle WT: The inner jet of an active galactic nucleus as revealed by a radio-to-gamma-ray outburst. Nature; 2008 Apr 24;452(7190):966-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They possess oppositely directed plasma jets emanating at near light speeds from accreting supermassive black holes.
  • According to theoretical models, such jets are propelled by magnetic fields twisted by differential rotation of the black hole's accretion disk or inertial-frame-dragging ergosphere.
  • Here we report sequences of high-resolution radio images and optical polarization measurements of the blazar BL Lacertae.
  • The data reveal a bright feature in the jet that causes a double flare of radiation from optical frequencies to TeV gamma-ray energies, as well as a delayed outburst at radio wavelengths.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nature. 2008 Apr 24;452(7190):945-6 [18432234.001]
  • (PMID = 18432239.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


52. Singh V, Kanaujia A, Singh GP: Efficacy of caudal butorphanol. Indian J Pediatr; 2006 Feb;73(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean duration of analgesia was maximum in group BL (14.5 +/- 3.5 hr, P<0.001), than in group L (8.8 +/- 4.8 hr) and group B (6.8 +/- 2.9 hr).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Anaesth. 1994 Mar;72(3):258-62 [8130041.001]
  • [Cites] Acta Anaesthesiol Scand. 2001 Jul;45(6):786-9 [11421842.001]
  • [Cites] Anesth Analg. 2000 May;90(5):1029-33 [10781448.001]
  • [Cites] Br J Anaesth. 1990 Apr;64(4):430-5 [1970738.001]
  • [Cites] Physiol Behav. 1999 Jun;66(4):627-37 [10386907.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD003005 [12804449.001]
  • [Cites] Anesth Analg. 1987 Sep;66(9):887-93 [3113291.001]
  • [Cites] Anesthesiology. 1982 Jun;56(6):431-6 [7081727.001]
  • (PMID = 16514225.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anesthetics, Local; QV897JC36D / Butorphanol; Y8335394RO / Bupivacaine
  •  go-up   go-down


53. Klein G, Klein E, Kashuba E: Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun; 2010 May 21;396(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Still, EBV became known first in 1964, in a rare, geographically prevalent malignant lymphoma of B-cell origin, Burkitt lymphoma BL.
  • Consequently EBV was classified therefore as a potentially tumorigenic virus.
  • The expression of EBV encoded genes is regulated by the cell phenotype.
  • The virus genome can be found in malignancies originating from cell types other than the B-lymphocyte.
  • Even in the EBV infected B-cell, the direct transforming capacity is restricted to a defined window of differentiation.
  • A complex interaction between virally encoded proteins and B-cell specific cellular proteins constitute the proliferation inducing program.
  • The growth promoting EBV encoded genes are not expressed in the virus carrying BL cells.
  • Still, EBV seems to contribute to the etiology of this tumor by modifying events that influence cell survival and proliferation.
  • We describe a possible growth promoting mechanism in the genesis of Burkitt lymphoma that depends on the presence of EBV.
  • [MeSH-major] B-Lymphocytes / virology. Burkitt Lymphoma / virology. Herpesvirus 4, Human / growth & development
  • [MeSH-minor] Cell Cycle. E2F1 Transcription Factor / metabolism. Epstein-Barr Virus Nuclear Antigens / metabolism. Gene Expression Regulation, Viral. Humans. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494113.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 100
  •  go-up   go-down


54. Orem J, Maganda A, Mbidde EK, Weiderpass E: Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection. Pediatr Blood Cancer; 2009 Apr;52(4):455-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection.
  • BACKGROUND: Characteristics of children with Burkitt lymphoma (BL) and HIV infection have not been described in Uganda before.
  • PROCEDURE: We reviewed records at Uganda Cancer Institute (UCI) for years 1994-2004, to compare clinical features and outcome of BL in children who are HIV positive and negative (HIV+, HIV-).
  • One hundred seventy-one cases (75%) had facial tumor (HIV+ 71.4%, HIV- 76.6%).
  • HIV positive children presented significantly with extrafacial disease (lymphadenopathy 67%, hepatic masses 51%, and thoracic masses 10%).
  • Presentation with advanced stage disease occurred more frequently in HIV positive patients compared to HIV negative patients.
  • CONCLUSIONS: BL in Uganda presents frequently with facial disease irrespective of HIV status.
  • However HIV+ BL also presents commonly with extra facial sites, mainly lymphadenopathy.
  • There is no difference in response to treatment with chemotherapy, but HIV+ BL patients have poorer survival.
  • There is need for further characterization of BL in Uganda to understand the role of HIV in disease process and outcome.
  • [MeSH-major] Burkitt Lymphoma / complications. Burkitt Lymphoma / pathology. HIV Infections / complications. HIV Infections / pathology


55. Fukuda M, Kurosaki H, Sairenji T: Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation. J Med Virol; 2006 Nov;78(11):1456-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
  • Transforming growth factor (TGF)-beta1 induces not only cell growth inhibition or apoptosis but also Epstein-Barr virus (EBV) reactivation in some Burkitt's lymphoma (BL) cell lines.
  • The purpose of this study was to define the role of TGF-beta signaling molecules in response to TGF-beta1-mediated cell growth inhibition, apoptosis, and EBV reactivation in BL cell lines.
  • First, we confirmed the effect of TGF-beta1 on the cell growth and EBV reactivation in six BL cell lines.
  • TGF-beta1 induced cell growth inhibition and EBV reactivation in these cell lines but did not in Akata cells.
  • All cell lines expressed TGF-beta type I receptor, Smad2, Smad3, and Smad4.
  • TGF-beta type II receptor (R-II) was expressed in all cell lines except Akata cells.
  • [MeSH-minor] Cell Line. Gene Expression Regulation. Humans. Protein-Serine-Threonine Kinases. Signal Transduction

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998876.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


56. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • PURPOSE: We studied the incidence, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since 1964.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Available histologic analysis of tumor tissue showed that 75% were CD20 positive and that 62% were EBV positive; EBV-positive tumors occurred sooner after SOT than EBV-negative tumors (mean, 29 v 66 months).
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Most of these lymphomas are CD20 positive.
  • Follicular lymphoma is unusual.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects


57. Sánchez-García J, Serrano J, Gómez P, Martínez F, Martín C, Román-Gómez J, Rodríguez A, Herrera C, García JM, Alvarez MA, Torres A: The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica; 2006 Mar;91(3):340-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse.
  • However, mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly understood.
  • DESIGN AND METHODS: We used multiparameter flow-cytometry to quantify pro-B (CD19+CD10+CD34+), pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT.
  • RESULTS: Acute GVHD of grades II-IV is associated with a strong inhibition of normal donor-derived pro-B and pre-B precursors at days +30 and +60 post-SCT.
  • Patients who develop chronic GVHD have lower percentages of marrow B-cell precursors during the first year after SCT.
  • Likewise, recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chronic GVHD.
  • Induction of GVHD as treatment of increasing amounts of leukemia cells causes inhibition of both normal and malignant B compartments even in the absence of steroid therapy.
  • INTERPRETATION AND CONCLUSIONS: We conclude that the development of GVHD after allogeneic SCT is associated with a non-specific inhibition of B-lymphopoiesis.
  • [MeSH-major] Burkitt Lymphoma / immunology. Graft vs Host Disease / immunology. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / pathology. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cell Lineage. Child. Child, Preschool. Chronic Disease. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Prospective Studies. Transplantation, Homologous


58. Tanaka G, Kanaji S, Hirano A, Arima K, Shinagawa A, Goda C, Yasunaga S, Ikizawa K, Yanagihara Y, Kubo M, Kuriyama-Fujii Y, Sugita Y, Inokuchi A, Izuhara K: Induction and activation of the aryl hydrocarbon receptor by IL-4 in B cells. Int Immunol; 2005 Jun;17(6):797-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified IL-4- or IL-13-inducible genes in a human Burkitt lymphoma cell line, DND-39, using microarray technology, in which the AHR gene was included.
  • AhR activated by IL-4 caused expression of a xenobiotic-metabolizing gene, CYP1A1, and TCDD synergistically acted on the induction of this gene by IL-4.
  • [MeSH-minor] Animals. Burkitt Lymphoma / enzymology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Cell Line. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cytochrome P-450 CYP1A1 / metabolism. Environmental Pollutants / toxicity. Humans. Interleukin-13 / pharmacology. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Plasmids. Tetrachlorodibenzodioxin / toxicity. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899923.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Interleukin-13; 0 / Receptors, Aryl Hydrocarbon; 207137-56-2 / Interleukin-4; DO80M48B6O / Tetrachlorodibenzodioxin; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


59. Asito AS, Piriou E, Odada PS, Fiore N, Middeldorp JM, Long C, Dutta S, Lanar DE, Jura WG, Ouma C, Otieno JA, Moormann AM, Rochford R: Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer; 2010;5:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.
  • BACKGROUND: Endemic Burkitt's lymphoma (BL) is an extranodal tumor appearing predominantly in the jaw in younger children while abdominal tumors predominate with increasing age.
  • Previous studies have identified elevated levels of antibodies to Plasmodium falciparum schizont extracts and Epstein-Barr virus (EBV) viral capsid antigens (VCA) in endemic BL relative to malaria exposed controls.
  • However, these studies have neither determined if there were any differences based on the site of clinical presentation of the tumor nor examined a broader panel of EBV and P. falciparum antigens.
  • METHODS: We used a suspension bead Luminex assay to measure the IgG levels against EBV antigens, VCA, EAd, EBNA-1 and Zta as well as P. falciparum MSP-1, LSA-1, and AMA-1 antigens in children with BL (n = 32) and in population-based age-and sex-matched controls (n = 25) from a malaria endemic region in Western Kenya with high incidence of BL.
  • RESULTS: Relative to healthy controls, BL patients had significantly increased anti-Zta (p = 0.0017) and VCA IgG levels (p < 0.0001) and plasma EBV viral loads (p < 0.0001).
  • In contrast, comparable IgG levels to all P. falciparum antigens tested were observed in BL patients compared to controls.
  • Interestingly, when we grouped BL patients into those presenting with abdominal tumors or with jaw tumors, we observed significantly higher levels of anti-Zta IgG levels (p < 0.0065) and plasma EBV viral loads (p < 0.033) in patients with abdominal tumors compared to patients with jaw tumors.
  • CONCLUSION: Elevated antibodies to Zta and elevated plasma EBV viral load could be relevant biomarkers for BL and could also be used to confirm BL presenting in the abdominal region.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):377-88 [19619657.001]
  • [Cites] J Gen Virol. 1995 Jun;76 ( Pt 6):1393-400 [7540196.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):13-9 [8014488.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Lancet. 1977 Feb 12;1(8007):335-8 [64861.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):549-52 [15086279.001]
  • [Cites] Cytometry. 2002 Oct 15;50(5):239-42 [12360572.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1721-6 [19089927.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Clin Vaccine Immunol. 2008 Nov;15(11):1684-8 [18768669.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] PLoS One. 2008;3(6):e2505 [18560562.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] J Clin Virol. 2008 Feb;41(2):96-103 [18024156.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Singapore Med J. 2006 Sep;47(9):803-7 [16924363.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4059-66 [15736452.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S111-6 [15622609.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1108-15 [10191211.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 May-Jun;17(3):391-400 [9185219.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] J Med Virol. 2009 Jun;81(6):1088-93 [19382256.001]
  • (PMID = 20667138.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923120
  •  go-up   go-down


60. Kangwansupamonkon W, Lauruengtana V, Surassmo S, Ruktanonchai U: Antibacterial effect of apatite-coated titanium dioxide for textiles applications. Nanomedicine; 2009 Jun;5(2):240-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its antibacterial performance was observed under black light, visible light, and dark conditions.
  • The effect of irradiation source on antimicrobial activity of coated cotton fabrics was examined, wherein black-light irradiation demonstrated higher antibacterial activity than either visible-light irradiation or dark conditions.
  • Our findings suggest that the presence of apatite-coated TiO2 shows antibacterial activity in the presence of black light or visible light, suggesting its potential use in reducing the risk of microorganism transmission for textile applications.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223243.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Apatites; 0 / Coated Materials, Biocompatible; 15FIX9V2JP / titanium dioxide; D1JT611TNE / Titanium
  •  go-up   go-down


61. Sun BW, Shi GS, Zhang P, Zou XQ, Chen X: [Inhibitive effect of exogenous carbon monoxide-releasing molecules 2 on tissue factor expression in sepsis]. Zhonghua Shao Shang Za Zhi; 2009 Apr;25(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-five C57 BL/6 male mice were randomly divided into NC (without treatment, n = 5), CLP (n = 5) and CLP + CORM-2 (with treatment of 8 mg/kg CROM-2 after CLP, n = 5) groups.

  • MedlinePlus Health Information. consumer health - Sepsis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799035.001).
  • [ISSN] 1009-2587
  • [Journal-full-title] Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
  • [ISO-abbreviation] Zhonghua Shao Shang Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lipoproteins; 0 / NF-kappa B; 0 / Organometallic Compounds; 0 / lipoprotein-associated coagulation inhibitor; 0 / tricarbonyldichlororuthenium (II) dimer; 9035-58-9 / Thromboplastin
  •  go-up   go-down


62. D'Alessandro DM, Dinolfo PH, Davies MS, Hupp JT, Keene FR: Underlying spin-orbit coupling structure of intervalence charge transfer bands in dinuclear polypyridyl complexes of ruthenium and osmium. Inorg Chem; 2006 Apr 17;45(8):3261-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mixed-valence systems meso- and rac-[{M(bpy)2}2(mu-BL)]5+ {M = Ru, Os; BL = a series of polypyridyl bridging ligands such as 2,3-bis(2-pyridyl)benzoquinoxaline (dpb)} are characterized by multiple intervalence charge transfer (IVCT) and interconfigurational (IC) bands in the mid-infrared and near-infrared (NIR) regions.
  • An increase in the separation between the IC bands as BL is varied reflects the increase in the degree of electronic coupling through the series of ruthenium and osmium complexes.
  • Stark effect measurements reveal small dipole moment changes accompanying IVCT excitation in support of the localized-to-delocalized or delocalized classification for the dinuclear ruthenium and osmium systems.


63. Kino K, Nakazawa Y, Yagasaki M: Dipeptide synthesis by L-amino acid ligase from Ralstonia solanacearum. Biochem Biophys Res Commun; 2008 Jul 4;371(3):536-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a novel method for effective production of dipeptides using l-amino acid alpha-ligase (Lal) is presented.
  • Lal, which is only identified in Bacillus subtilis, catalyzes dipeptide synthesis from unprotected amino acids in an ATP-dependent manner.
  • However, not all the dipeptide can be synthesized by Lal from B. subtilis (BsLal) due to its substrate specificity.
  • Here, we attempted to find a novel Lal exhibiting different substrate specificity from BsLal.
  • By in silico screening based on the amino acid sequence of BsLal, RSp1486a an unknown protein from Ralstonia solanacearum was found to show the Lal activity.

  • COS Scholar Universe. author profiles.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445480.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Plant Proteins; EC 6.3.2.- / Peptide Synthases
  •  go-up   go-down


64. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C: Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood; 2010 Apr 15;115(15):3089-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
  • PAX5 is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL).
  • Furthermore, malignant cells carrying PAX5 fusion genes displayed a simple karyotype.
  • Our data shed more light on the high variability of PAX5 alterations in B-ALL.
  • Therefore, it is probable that gene fusions occur early, whereas deletions should be regarded as a late/secondary event.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Cytogenetic Analysis. Mutation / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160164.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human
  •  go-up   go-down


65. Zhao J, Yang CH, Hu M, Liu ZQ: [Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Dec;29(12):2387-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer].
  • OBJECTIVE: To determine the concentration of ginsenoside Rb(2) and study the absorption characteristics of ginsenoside Rb(2) in Caco-2 cell monolayer.
  • RESULTS: P(app(AP-BL)) was 3.27 x 10(-7) cm.s(-1), P(app(BL-AP)) was 3.16 x 10(-6) cm.s(-1), and the efflux ratio (P(app(BL-AP))/P(app(AP-BL))) was 9.63.
  • CONCLUSION: The absorption characteristics of ginsenoside Rb(2) in Caco-2 cell model have been demonstrated.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20034882.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ginsenosides; 11021-13-9 / ginsenoside Rb2
  •  go-up   go-down


66. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK: Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res; 2009 May;26(5):1270-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958406.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY009171; United States / NEI NIH HHS / EY / R01 EY010659; United States / NEI NIH HHS / EY / R01EY09171-14; United States / NEI NIH HHS / EY / R01EY10659-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 63937KV33D / Erythromycin
  • [Other-IDs] NLM/ NIHMS680905; NLM/ PMC4516224
  •  go-up   go-down


67. Pereira JA, Pleguezuelos E, Merí A, Molina-Ros A, Molina-Tomás MC, Masdeu C: Effectiveness of using blended learning strategies for teaching and learning human anatomy. Med Educ; 2007 Feb;41(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blended learning strategies were employed in 1 group (BL group, n = 69); the other (TT group; n = 65) received traditional teaching aided by complementary material that could be accessed on the Internet.
  • RESULTS: The average marks presented statistically significant differences (BL 6.3 versus TT 5.0; P < 0.0001).
  • The percentage pass rate for the subject in the first call was higher in the BL group (87.9% versus 71.4%; P = 0.02), reflecting a lower incidence of students who failed to sit the examination (BL 4.3% versus TT 13.8%; P = 0.05).
  • [MeSH-major] Anatomy / education. Clinical Competence / standards. Education, Medical, Undergraduate / methods. Learning. Teaching / methods

  • MedlinePlus Health Information. consumer health - Anatomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269953.001).
  • [ISSN] 0308-0110
  • [Journal-full-title] Medical education
  • [ISO-abbreviation] Med Educ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Meyer M, Stähler J, Kusmierek DO, Wolf M, Bovensiepen U: Determination of the electron's solvation site on D2O/Cu(111) using Xe overlayers and femtosecond photoelectron spectroscopy. Phys Chem Chem Phys; 2008 Aug 28;10(32):4932-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the electron's solvation site on D2O/Cu(111) using Xe overlayers and femtosecond photoelectron spectroscopy.
  • We investigate the binding site of solvated electrons in amorphous D(2)O clusters and D(2)O wetting layers adsorbed on Cu(111) by means of two-photon photoelectron (2PPE) spectroscopy.
  • We employ an empirical model calculation to analyse the rate of electron transfer back to the substrate and the energetic stabilization of the solvated electrons, which allows further insight into the binding site for clusters.
  • Therefore, we attribute the transition from surface- to bulk-solvation to the coalescence of the clusters to a closed ice film occurring at a nominal coverage of 2-3 BL, while the distance of the binding sites to the metal-ice interface is maintained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688537.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Gal SZ, Wang J: [Clinical observation on drug-separated moxibustion at the navel for anti-aging]. Zhongguo Zhen Jiu; 2007 Jun;27(6):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on drug-separated moxibustion at the navel for anti-aging].
  • OBJECTIVE; To observe clinical therapeutic effect and the mechanism of drug-separated moxibustion at the navel for delaying aging.
  • The group of drug-separated moxibustion at the navel (n=30) were treated with drug-separated moxibustion at the navel, twice each week; the acupuncture group (n=21) with acupuncture at Shenshu (BL 23) and Taixi (KI 3) as main points once each day; the western medicine group (n=20) with oral administration of vitamin E capsules, 0.
  • Their clinical therapeutic effects, and changes of cumulative scores, serum SOD activities and MDA contents after treatment were compared among the 3 groups.
  • RESULTS: After treatment, clinical symptoms in the 3 groups very significantly improved (P < 0.01), with the group of drug-separated moxibustion at the navel more significantly improved (P < 0.01); in the 3 groups, SOD activities significantly increased (P < 0.01) and serum MDA contents significantly decreased (P < 0.01), and SOD activity and MDA content in the group of drug-separated moxibustion at the navel were not significantly different from those in the acupuncture group (P > 0.05), but significantly different from those in the western medicine group (P < 0.05).

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663099.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


70. Schepel SA, Fox AJ, Miyauchi JT, Sou T, Yang JD, Lau K, Blum AW, Nicholson LK, Tiburcy F, Nachman RJ, Piermarini PM, Beyenbach KW: The single kinin receptor signals to separate and independent physiological pathways in Malpighian tubules of the yellow fever mosquito. Am J Physiol Regul Integr Comp Physiol; 2010 Aug;299(2):R612-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Now using the kinins of Aedes (the aedeskinins), we have found that in isolated Aedes Malpighian tubules all three aedeskinins (1 microM) significantly 1) increased the rate of fluid secretion (V(S)), 2) hyperpolarized the basolateral membrane voltage (V(bl)), and 3) decreased the input resistance (R(in)) of principal cells, consistent with the known increase in the Cl(-) conductance of the paracellular pathway in Aedes Malpighian tubules.
  • While the three aedeskinins triggered effects on V(bl), R(in), and V(S), synthetic kinin analogs, which contain modifications of the COOH-terminal amide pentapeptide core sequence critical for biological activity, displayed variable effects.
  • For example, kinin analog 1578 significantly stimulated V(S) but had no effect on V(bl) and R(in), whereas kinin analog 1708 had no effect on V(S) but significantly affected V(bl) and R(in).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Biol. 1999 Dec;202(Pt 24):3667-76 [10574744.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 2):R339-45 [2579589.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13727-36 [10788493.001]
  • [Cites] J Comp Neurol. 2000 Sep 11;425(1):45-57 [10940941.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Oct;279(4):F747-54 [10997925.001]
  • [Cites] Pflugers Arch. 1985;405 Suppl 1:S17-22 [4088834.001]
  • [Cites] Life Sci. 1989;44(18):1259-66 [2716471.001]
  • [Cites] Methods Enzymol. 1990;191:167-226 [2074756.001]
  • [Cites] Am J Physiol. 1991 Sep;261(3 Pt 1):C521-9 [1653525.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 2):R609-14 [1415649.001]
  • [Cites] J Membr Biol. 1993 Feb;132(1):63-76 [8459448.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 29;202(2):715-9 [8048942.001]
  • [Cites] Peptides. 1995;16(1):95-104 [7716080.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21722-8 [7665591.001]
  • [Cites] J Exp Biol. 1996 May;199(Pt 5):1163-75 [8786336.001]
  • [Cites] Peptides. 1996;17(2):327-36 [8801541.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10402-7 [9099680.001]
  • [Cites] Ann N Y Acad Sci. 1997 Apr 24;814:342-5 [9160988.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):963-1032 [9354810.001]
  • [Cites] Peptides. 1998;19(3):469-80 [9533634.001]
  • [Cites] J Exp Biol. 1998 Jun;201(Pt 11):1753-62 [9576886.001]
  • [Cites] Mol Pharmacol. 1998 Jul;54(1):94-104 [9658194.001]
  • [Cites] Cell Tissue Res. 1998 Dec;294(3):549-60 [9799471.001]
  • [Cites] Peptides. 1999;20(1):1-10 [10098618.001]
  • [Cites] J Exp Biol. 2004 Dec;207(Pt 26):4573-86 [15579553.001]
  • [Cites] Insect Mol Biol. 2005 Jan;14(1):55-67 [15663775.001]
  • [Cites] Mol Interv. 2005 Jun;5(3):154-7 [15994454.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Nov;289(5):C1261-7 [15987771.001]
  • [Cites] Arch Insect Biochem Physiol. 2006 Jul;62(3):128-40 [16783824.001]
  • [Cites] Biopolymers. 2007;88(1):76-82 [17117460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10691-6 [17563389.001]
  • [Cites] Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):332-8 [17400222.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):383-7 [17952055.001]
  • [Cites] J Exp Biol. 2008 Feb;211(Pt 3):409-22 [18203997.001]
  • [Cites] Peptides. 2008 Feb;29(2):302-9 [18207610.001]
  • [Cites] Gen Comp Endocrinol. 2009 May 15;162(1):122-8 [18983996.001]
  • [Cites] Biophys J. 2009 Oct 21;97(8):2202-11 [19843452.001]
  • [Cites] J Exp Biol. 2009 Dec;212(Pt 23):3802-9 [19915121.001]
  • [Cites] Insect Biochem Mol Biol. 2000 Dec;30(12):1147-59 [11044661.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):185-92 [11087995.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5375-83 [11087732.001]
  • [Cites] J Exp Biol. 2001 Sep;204(Pt 17):3075-84 [11551995.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E1015-21 [11595658.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Sep;283(3):F499-508 [12167601.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):957-62 [12183652.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38810-7 [12163486.001]
  • [Cites] J Exp Biol. 2003 Jan;206(Pt 2):233-43 [12477894.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Mar;284(3):C718-28 [12444020.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2003 Sep;12(5):543-50 [12920403.001]
  • [Cites] J Exp Biol. 2004 Jan;207(Pt 3):519-26 [14691099.001]
  • [Cites] Ann N Y Acad Sci. 1999;897:361-73 [10676463.001]
  • (PMID = 20538895.001).
  • [ISSN] 1522-1490
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG029385
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorides; 0 / Insect Proteins; 0 / Kinins; 0 / Receptors, G-Protein-Coupled; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium
  • [Other-IDs] NLM/ PMC3774469
  •  go-up   go-down


71. Futagbi G, Welbeck JE, Tetteh JK, Hviid L, Akanmori BD: Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma. Malar J; 2007;6:69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma.
  • BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases.
  • It is suspected that the polyclonal B-cell activation in P. falciparum malaria may precipitate a breakdown in homeostatic T-cell control of EBV-immortalized B-cell proliferation.
  • Previous studies have suggested that a particular T-cell subset, characterized by expression of Vdelta1+ gammadelta T-cell receptors, is important for maintaining B-cell homeostasis, both in P. falciparum- exposed populations and in individuals subject to polyclonal B-cell activation of other aetiology.
  • The objective of the present study was, therefore, to characterize lymphocyte phenotypes and to investigate possible differences in T-cell subset composition and activation status in P. falciparum-exposed Ghanaian children with and without eBL.
  • METHODS: Venous blood samples in heparin from 21 eBL patients (mean age: 7.0 years; range: 3-11 years), referred to the Burkitt's Tumour Centre at Korle-Bu Teaching Hospital, Accra and 15 healthy, age and sex matched children, were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, R-phycoerythrin (RPE)- and RPE-Cy5-conjugated antibodies (CD3, CD4, CD8, CD25, CD69, CD95, HLA-DR, TCR-gammadelta, Vdelta1, Vdelta3, Vgamma9 and B-cells) and acquired on a flow cytometer.
  • The data supports the hypothesis of a regulatory role for Vdelta1+ TcR-gammadelta T-cells in maintaining B-cell homeostasis and provides insights into the pathogenesis of eBL.
  • [MeSH-major] Burkitt Lymphoma / immunology. Lymphocyte Activation. Malaria, Falciparum / complications. Malaria, Falciparum / immunology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 [1931134.001]
  • [Cites] J Immunol. 1992 Dec 15;149(12):3984-9 [1334108.001]
  • [Cites] J Immunol Methods. 1993 Jan 4;157(1-2):135-42 [8423356.001]
  • [Cites] Am J Trop Med Hyg. 1994 Sep;51(3):372-9 [7524374.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3199-204 [7528674.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):464-74 [8977224.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4359-62 [8926112.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58 [10100275.001]
  • [Cites] Am J Trop Med Hyg. 1991 May;44(5):571-7 [2063961.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):797-805 [10837407.001]
  • [Cites] Infect Immun. 2001 May;69(5):3190-6 [11292740.001]
  • [Cites] J Natl Cancer Inst. 1969 Jan;42(1):19-28 [4303830.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1977;71(5):408-10 [304268.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):41-5 [352584.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Dec;22(6):662-8 [214405.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):398 [6095098.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1262-74 [3114436.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1249-53 [1674690.001]
  • (PMID = 17521425.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1894981
  •  go-up   go-down


72. Cohn E, Ossowski L, Bertran S, Marzan C, Farias EF: RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis. Breast Cancer Res; 2010;12(5):R79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used whole mounts analysis, stem cells/progenitor quantification, mammary gland repopulation, Q-PCR, test of tumor-free survival, tumor fragments and cell transplantation.
  • RESULTS: In 2 genetic backgrounds (129/Bl-6 and FVB) the neo-natal RARα1/KO-mammary epithelial tree was 2-fold larger and the pubertal tree had 2-fold more branch points and 5-fold more mature end buds, a phenotype that was predominantly epithelial cell autonomous.
  • The stem/progenitor compartment of the RARα1/KO mammary, defined as CD24(low)/ALDH(high activity) was increased by a median 1.7 fold, but the mammary stem cell (MaSC)-containing compartment, (CD24(low)/CD29(high)), was larger (~1.5 fold) in the wt-glands, and the mammary repopulating ability of the wt-gland epithelium was ~2-fold greater.
  • The tumor-free survival of RARα1/KO-wnt1 mice was significantly (p=0.0002, Kaplan Meier) longer, the in vivo growth of RARα1/KO-wnt1 transplanted tumor fragments was significantly (p=0.01) slower and RARα1/KO-wnt1 tumors cell suspension produced tumors after much longer latency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Dev Dyn. 2005 Dec;234(4):892-9 [16217742.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R7 [16417656.001]
  • [Cites] Breast Cancer Res. 2006;8(1):201 [16524451.001]
  • [Cites] Mol Cancer. 2006;5:12 [16563162.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1283-93 [16682494.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):213-28 [17120154.001]
  • [Cites] Development. 2007 Mar;134(6):1231-42 [17287253.001]
  • [Cites] Vitam Horm. 2007;75:69-95 [17368312.001]
  • [Cites] Transgenic Res. 2007 Apr;16(2):193-201 [17206489.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):124-36 [17873345.001]
  • [Cites] J Cell Biochem. 2007 Nov 1;102(4):886-98 [17902161.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7526-34 [17546050.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3248-60 [17955177.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):364-71 [17975224.001]
  • [Cites] Development. 2008 Mar;135(6):995-1003 [18296651.001]
  • [Cites] Breast Cancer Res. 2008;10(3):402; author reply 403 [18522763.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7711-7 [18829523.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Pathol. 2009 Jan;217(2):229-41 [19009588.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Nucl Recept Signal. 2009;7:e006 [19471585.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:469-78 [19022771.001]
  • [Cites] BMC Cancer. 2009;9:325 [19751508.001]
  • [Cites] Genes Dev. 2009 Nov 15;23(22):2563-77 [19933147.001]
  • [Cites] Oncogene. 2010 Jun 24;29(25):3665-76 [20453882.001]
  • [Cites] Curr Biol. 1999 Dec 2;9(23):1415-8 [10607566.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1002-9 [10713683.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):475-80 [10716965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3044-9 [10737785.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1235-40 [11062534.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1439-47 [12368216.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:59-72 [14521516.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48137-45 [12972427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 [15020770.001]
  • [Cites] Fed Proc. 1976 May 1;35(6):1332-8 [770206.001]
  • [Cites] Nutr Rev. 1978 Jan;36(1):16-9 [342996.001]
  • [Cites] Exp Cell Biol. 1988;56(5):254-63 [3229553.001]
  • [Cites] Prev Med. 1989 Sep;18(5):576-91 [2694156.001]
  • [Cites] Biomed Pharmacother. 1991;45(4-5):145-56 [1657236.001]
  • [Cites] Development. 1994 Oct;120(10):2749-71 [7607068.001]
  • [Cites] J Cell Biochem Suppl. 1994;20:32-54 [7616752.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1138-49 [8622658.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):619-27 [9052765.001]
  • [Cites] Cell Growth Differ. 1997 Jun;8(6):631-41 [9185997.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2642-50 [9205071.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1741-9 [9403724.001]
  • [Cites] Expert Rev Mol Med. 2004 Nov 30;6(25):1-23 [15569396.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):17-24 [15886883.001]
  • [Cites] Endocrinology. 2005 Aug;146(8):3577-88 [15878961.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8193-9 [16166294.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • (PMID = 20923554.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA54273
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Antigens, CD29; 0 / Isoenzymes; 0 / Receptors, Retinoic Acid; 0 / Wnt1 Protein; 0 / Wnt1 protein, mouse; 0 / retinoic acid receptor alpha; EC 1.2.1.- / aldehyde dehydrogenase 1; EC 1.2.1.36 / Retinal Dehydrogenase
  •  go-up   go-down


73. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
  • Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+).
  • The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients with DLBCL.
  • Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


74. Caron G, Le Gallou S, Lamy T, Tarte K, Fest T: CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol; 2009 Jun 15;182(12):7595-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rapidly dividing centroblasts and the nondividing centrocytes represent the two major B cell subsets present in germinal center and also the most common normal counterparts for a majority of lymphomas.
  • By gene set enrichment analysis we demonstrated that the centroblastic gene expression signature was significantly enriched in Burkitt's lymphomas.
  • Collectively, our findings show that CXCR4 expression can properly separate human centroblasts from centrocytes and offer now the possibility to have purified normal counterparts of mature B cell-derived malignancies.
  • [MeSH-major] B-Lymphocytes / cytology. B-Lymphocytes / immunology. Cell Cycle. Cell Differentiation / immunology. Germinal Center / cytology. Germinal Center / immunology. Receptors, CXCR4 / immunology
  • [MeSH-minor] Cell Membrane / immunology. Cell Membrane / metabolism. Cells, Cultured. Gene Expression Profiling. Gene Expression Regulation / immunology. Humans. Immunoglobulin G / immunology. Transcription, Genetic / genetics. Trihexosylceramides / immunology

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494283.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, CXCR4; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


75. Santamaría-Quesada C, Vargas M, Venegas P, Calvo M, Obando C, Valverde B, Cartín W, Carrillo JM, Jimenez R, González M: Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica. J Pediatr Hematol Oncol; 2009 Feb;31(2):131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica.
  • In Central America, nearly 70% of pediatric cancer is related to hemato-oncologic disorders, especially acute lymphoblastic leukemia (ALL).
  • Preliminary studies have described a high incidence of childhood leukemia in these countries; however, no molecular analyses of these malignancies have yet been carried out.
  • We studied diagnostic samples from 84 patients from the National Children's Hospital in San Jose, Costa Rica (65 precursor B-ALL, 5 T-cell ALL, and 14 acute myeloblastic leukemia).
  • The observed rate of leukemia was 52.2 cases per million children per year.
  • None of the T-cell ALL cases were positive for either SIL-TAL1 or HOX11L2.
  • Within 14 acute myeloblastic leukemia patients, we confirmed 2 cases with FLT3-internal tandem duplication+, 1 patient with AML1-ETO, and only 1 case carrying a PML-RARalpha rearrangement.
  • The present study confirms the relatively high incidence of pediatric leukemia in Costa Rica and constitutes the first report regarding the incidence of the main molecular alterations of childhood leukemia in our region.
  • [MeSH-major] Leukemia / epidemiology. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Child. Costa Rica / epidemiology. Cytogenetic Analysis. Gene Rearrangement. Humans. Mutation. Oncogene Proteins, Fusion / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194200.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


76. Pérez-Durán P, de Yebenes VG, Ramiro AR: Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis; 2007 Dec;28(12):2427-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two of these mechanisms, somatic hypermutation (SHM) and class switch recombination (CSR), are initiated by activation-induced cytidine deaminase (AID) upon antigen stimulation of mature B cells.
  • AID deaminates cytosines on the DNA of Ig genes thereby generating a lesion that can be processed into a mutation (SHM) or a DNA double-strand break followed by a recombination reaction (CSR).
  • Most lymphocyte neoplasias are originated from mature B cells and harbour hallmark chromosome translocations of lymphomagenic potential, such as the c-myc/IgH translocations found in Burkitt lymphomas.
  • In addition, evidence is accumulating that AID expression can be induced in B cells independently of the germinal centre environment, such as in response to some viral infections, and occasionally in non-B cells, at least in certain inflammation-associated neoplasic situations.
  • [MeSH-major] Antibodies / immunology. Cell Transformation, Neoplastic. Cytidine Deaminase / immunology
  • [MeSH-minor] Animals. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Chromosome Aberrations. Gene Rearrangement. Genes, Immunoglobulin / immunology. Germinal Center / immunology. Germinal Center / pathology. Humans. Immunoglobulin Class Switching. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Recombination, Genetic. Somatic Hypermutation, Immunoglobulin. Tumor Suppressor Proteins / physiology

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804422.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Tumor Suppressor Proteins; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 88
  •  go-up   go-down


77. Gomez S, Uribe S, Onetto JE, Emilson CG: SEM analysis of sealant penetration in posterior approximal enamel carious lesions in vivo. J Adhes Dent; 2008 Feb;10(2):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each tooth was randomly assigned to mesial or distal surface application of a sealant in the lesion area and in surrounding sound enamel, with or without a bonding system.
  • Four groups were analyzed: a nonbonding group in the lesion area (NBL); a nonbonding group in sound enamel (NBS); a bonding group in the lesion area (BL) and a bonding group in sound enamel (BS).
  • CONCLUSION: The use of a bonding system prior to the application of a pit and fissure sealant on both lesion and sound enamel areas does not increase the resin penetration length under non-contaminated conditions.

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • Hazardous Substances Data Bank. SODIUM FLUORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512513.001).
  • [ISSN] 1461-5185
  • [Journal-full-title] The journal of adhesive dentistry
  • [ISO-abbreviation] J Adhes Dent
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cariostatic Agents; 0 / Clinpro Sealant; 0 / Composite Resins; 0 / Dentin-Bonding Agents; 0 / Fluorides, Topical; 0 / Organophosphonates; 0 / Pit and Fissure Sealants; 0 / Scotchbond etchant; 0 / single bond; 0 / sodium fluoride topical preparation; 454I75YXY0 / Bisphenol A-Glycidyl Methacrylate; 8ZYQ1474W7 / Sodium Fluoride; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


78. Grimbert P, Mansour H, Desvaux D, Roudot-Thoraval F, Audard V, Dahan K, Berrehar F, Dehoulle-Poillet C, Farcet JP, Lang P, Le Gouvello S: The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation; 2007 Feb 15;83(3):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection.
  • The interpretation of cellular infiltrate from renal transplant recipients with borderline (BL) changes is still a challenging problem.
  • To analyze the immune phenotype of such infiltrate, we quantified the mRNA expression of Foxp3 and interleukinL-10 and granzyme B (GB) in 15 kidney biopsies with BL changes.
  • Controls were patients presenting type IA acute rejection and nonrejecting patients.
  • Levels of Foxp3 mRNA in BL changes were intermediate between type IA acute rejection and nonrejecting controls.
  • BL changes T cells infiltrate expressed a significantly higher Foxp3/GB ratio than that in IA acute rejection.
  • These results suggest that T cell infiltrate from BL change exhibit a tolerogenic rather than a cytotoxic phenotype.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17297410.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 130068-27-8 / Interleukin-10; EC 3.4.21.- / Granzymes
  •  go-up   go-down


79. Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA: Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCV was associated with increased risk of diffuse large B-cell lymphoma [odds ratio (OR) 1.52, 95% confidence interval (95% CI) 1.05-2.18], Burkitt lymphoma (OR 5.21, 95% CI 1.62-16.8), follicular lymphoma (OR 1.88, 95% CI 1.17-3.02), marginal zone lymphoma (OR 2.20, 95% CI 1.22-3.95), and acute myeloid leukemia (OR 1.54, 95% CI 1.00-2.37).
  • Alcoholic hepatitis was associated with decreased risk of non-Hodgkin lymphoma overall, but increased risk of Burkitt lymphoma.
  • In summary, HCV, but not other causes of hepatitis, was associated with the elevated risk of non-Hodgkin lymphoma and acute myeloid leukemia.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Nov;107(2):353-6 [10583224.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Feb;16(2):215-9 [11207904.001]
  • [Cites] Eur J Clin Invest. 2001 Jul;31(7):628-38 [11454019.001]
  • [Cites] Acta Haematol. 2001;105(4):237-40 [11528098.001]
  • [Cites] Liver. 2001 Oct;21(5):335-41 [11589770.001]
  • [Cites] Jpn J Cancer Res. 2002 May;93(5):471-7 [12036441.001]
  • [Cites] Alcohol. 2002 May;27(1):17-21 [12062632.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3 [12142963.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Hematol J. 2003;4(5):303-9 [14502253.001]
  • [Cites] J Med Microbiol. 2004 Jan;53(Pt 1):21-9 [14663101.001]
  • [Cites] Haematologica. 2004 Jan;89(1):70-6 [14754608.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30 [15006919.001]
  • [Cites] Med Oncol. 2004;21(1):67-72 [15034216.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):81-5 [15185347.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):745-52 [15471561.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):182-8 [1983820.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):162-4 [8641648.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Mar;5(3):227-30 [8833624.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):101-4 [9013840.001]
  • [Cites] Arch Virol. 1997;142(3):545-55 [9349300.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3328-37 [9787170.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):14-8 [9987458.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):45-52 [10350331.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1476-82 [10424754.001]
  • [Cites] Eur J Haematol. 2005 Feb;74(2):158-65 [15654908.001]
  • [Cites] Hepatology. 2005 Mar;41(3):652-9 [15723449.001]
  • [Cites] Expert Opin Drug Saf. 2005 May;4(3):599-608 [15934864.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • [Cites] Haematologica. 2006 Apr;91(4):554-7 [16585021.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):197-203 [16684579.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2078-85 [17119031.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):132-7 [17635237.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):791-8 [17941950.001]
  • [Cites] J Hepatol. 1999;31 Suppl 1:88-91 [10622567.001]
  • (PMID = 18957521.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS65580; NLM/ PMC2597453
  •  go-up   go-down


80. Ermakov S, Malkin I, Keter M, Kobyliansky E, Livshits G: Family-based association study of polymorphisms in the RUNX2 locus with hand bone length and hand BMD. Ann Hum Genet; 2008 Jul;72(Pt 4):510-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This research was aimed to test the hypothesis of association of radiographic hand bone length (BL) and BMD with polymorphisms in the RUNX2 locus.
  • These SNPs and four pairwise haplotypes were tested for association with eight BL and BMD traits, adjusted for covariates.
  • We observed significant associations between polymorphisms linked to the RUNX2 P1 promoter and BL mean values for three studied bone groups: all 18 bones, proximal and medial bones (p = 0.0118, 0.0085, and 0.0056, respectively).
  • Associations with BL and BMD mean values for medial and proximal bones remained significant even after correction for multiple testing.
  • This study provides evidence of the association between polymorphisms linked to the two RUNX2 promoters and variability of hand BL and BMD.
  • [MeSH-major] Bone Density. Core Binding Factor Alpha 1 Subunit / genetics. Genetic Predisposition to Disease. Hand Bones / chemistry. Osteoporosis / genetics. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373722.001).
  • [ISSN] 0003-4800
  • [Journal-full-title] Annals of human genetics
  • [ISO-abbreviation] Ann. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / RUNX2 protein, human
  •  go-up   go-down


81. Bai RX, Li P: [Influence of mild moxibustion on androgenic hormone in male rats with partial androgen deficiency]. Zhen Ci Yan Jiu; 2007 Aug;32(4):229-33, 236
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty male SD rats (aged 12 months) were randomized into control, androlin (testosterone propionate) and moxibustion ["Shenshu" (BL 23), "Mingmen" (GV 4) and 'Guanyuan" (CV 4)] groups.

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907383.001).
  • [ISSN] 1000-0607
  • [Journal-full-title] Zhen ci yan jiu = Acupuncture research
  • [ISO-abbreviation] Zhen Ci Yan Jiu
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Androgens; 3XMK78S47O / Testosterone; WI93Z9138A / Testosterone Propionate
  •  go-up   go-down


82. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Münz C, Rochford R: Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer; 2009 Apr 1;124(7):1721-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.
  • Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life.
  • Epstein-Barr nuclear antigen 1 (EBNA1) is the sole viral latent antigen expressed in BL tumors.
  • Therefore, EBNA1-specific T cell responses were analyzed by IFN-gamma ELISPOT in Kenyan children with eBL and compared to healthy children with divergent malaria exposure.
  • CD8(+) T cell responses to EBV lytic and latent antigens not expressed in the tumors were similarly robust in eBL patients compared to healthy children.
  • In addition, CD4(+) T cell responses to a malaria protein, merozoite surface protein 1, were present in lymphoma patients.
  • This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated lymphoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1451-61 [18209040.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1371-4 [12958359.001]
  • [Cites] J Virol. 2003 Nov;77(22):12088-104 [14581546.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):6766-74 [14638762.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):459-70 [14769850.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):293-325 [15009803.001]
  • [Cites] IARC Sci Publ. 1985;(60):165-76 [2998987.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Immunity. 1997 Dec;7(6):791-802 [9430224.001]
  • [Cites] Nature. 1999 Jul 1;400(6739):73-7 [10403251.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S68-77 [15622605.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):165-72 [16415871.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1459-67 [16597877.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1138-46 [16985171.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):799-808 [17299709.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1593-603 [12133989.001]
  • (PMID = 19089927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NIAID NIH HHS / AI / AI4390; United States / FIC NIH HHS / TW / D43 TW006576; United States / NCI NIH HHS / CA / R01 CA101741; United States / NIAID NIH HHS / AI / U01 AI043906; United States / NIAID NIH HHS / AI / R01 AI043906; United States / NCI NIH HHS / CA / R01 CA134051; United States / NIAID NIH HHS / AI / K08 AI051565; United States / NCI NIH HHS / CA / CA101741; United States / FIC NIH HHS / TW / D43 TW006576-05; United States / NIAID NIH HHS / AI / K08-AI51565; United States / NIAID NIH HHS / AI / K08 AI051565-05; United States / NCI NIH HHS / CA / CA108609; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98574; NLM/ PMC2708320
  •  go-up   go-down


83. Atapattu DN, Czuprynski CJ: Mannheimia haemolytica leukotoxin induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway. Infect Immun; 2005 Sep;73(9):5504-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mannheimia haemolytica leukotoxin induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway.
  • Mannheimia haemolytica is a key pathogen in the bovine respiratory disease complex.
  • It produces a leukotoxin (LKT) that is an important virulence factor, causing cell death in bovine leukocytes.
  • The LKT binds to the beta(2) integrin CD11a/CD18, which usually activates signaling pathways that facilitate cell survival.
  • In this study, we investigated mechanisms by which LKT induces death in bovine lymphoblastoid cells (BL-3).
  • Incubation of BL-3 cells with a low concentration of LKT results in the activation of caspase-3 and caspase-9 but not caspase-8.
  • These data suggest that LKT induces apoptosis of BL-3 cells via a caspase-9-dependent mitochondrial pathway.
  • Furthermore, scanning electron micrographs of mitochondria from LKT-treated BL-3 cells revealed lesions in the outer mitochondrial membrane, which are larger than previous reports of the permeability transition pore through which cytochrome c is usually released.
  • [MeSH-minor] Animals. Caspase 3. Caspase 8. Caspase 9. Cattle. Cell Line, Transformed. Cytochromes c / metabolism. Cytotoxins / physiology. Down-Regulation. L-Lactate Dehydrogenase / metabolism. Membrane Potentials / drug effects. Up-Regulation. Virulence Factors / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1999 Feb 11;9(3):147-50 [10021389.001]
  • [Cites] FEMS Microbiol Lett. 1999 Oct 1;179(1):161-7 [10481101.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):33-4 [10485701.001]
  • [Cites] Mol Microbiol. 1999 Sep;33(6):1190-9 [10510233.001]
  • [Cites] Infect Immun. 2000 Jan;68(1):72-9 [10603370.001]
  • [Cites] Am J Vet Res. 2000 Jan;61(1):51-6 [10630778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):577-82 [10639121.001]
  • [Cites] Front Biosci. 2000 Apr 1;5:D438-51 [10762594.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell Res. 2000 Sep;10(3):213-20 [11032173.001]
  • [Cites] Am J Vet Res. 2001 Jan;62(1):136-41 [11197552.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):505-13 [11228543.001]
  • [Cites] Mol Cell Neurosci. 2001 Apr;17(4):761-7 [11312610.001]
  • [Cites] Nat Struct Biol. 2001 May;8(5):394-401 [11323712.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Infect Immun. 2001 Oct;69(10):6131-9 [11553552.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):R767-8 [11591332.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2922-33 [11711427.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):33024-34 [15166238.001]
  • [Cites] J Mol Histol. 2004 Jan;35(1):11-9 [15323345.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):752-62 [15340382.001]
  • [Cites] Acta Chem Scand B. 1979;B33(2):93-9 [219645.001]
  • [Cites] J Vet Intern Med. 1992 Jan-Feb;6(1):11-22 [1548621.001]
  • [Cites] Eur J Immunol. 1993 Aug;23(8):1859-65 [8344347.001]
  • [Cites] Infect Immun. 1995 Aug;63(8):3209-12 [7622250.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2687-94 [8698496.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Infect Immun. 1997 Sep;65(9):3719-24 [9284143.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):R1376-83 [9612405.001]
  • [Cites] Trends Cell Biol. 1998 Jul;8(7):267-71 [9714597.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1235-46 [9694712.001]
  • [Cites] FEBS Lett. 1998 Nov 13;439(1-2):168-72 [9849900.001]
  • [Cites] Microb Pathog. 1998 Dec;25(6):317-31 [9895270.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6627-36 [11726499.001]
  • [Cites] Acta Oncol. 2001;40(6):696-701 [11765063.001]
  • [Cites] Vet Microbiol. 2002 Feb 4;84(4):337-56 [11750142.001]
  • [Cites] Nature. 2002 May 2;417(6884):99-102 [11986672.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):349-55 [12054607.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6330-5 [12055249.001]
  • [Cites] Infect Immun. 2002 Aug;70(8):4336-43 [12117943.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):5058-64 [12183553.001]
  • [Cites] Anim Health Res Rev. 2002 Dec;3(2):69-82 [12665107.001]
  • [Cites] Cell Death Differ. 2003 Mar;10(3):335-44 [12700633.001]
  • [Cites] Am J Nephrol. 2003 May-Jun;23(3):140-51 [12624487.001]
  • [Cites] J Am Soc Nephrol. 2003 Jun;14(6):1427-34 [12761242.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):591-604 [12859673.001]
  • [Cites] Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):141-55 [14977177.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):106-17 [14980506.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 May;286(5):C1109-17 [15075210.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16194-205 [14960575.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):139-50 [15183529.001]
  • (PMID = 16113266.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Exotoxins; 0 / Virulence Factors; 0 / leukotoxin; 9007-43-6 / Cytochromes c; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1231077
  •  go-up   go-down


84. Kusao I, Agsalda M, Troelstrup D, Villanueva N, Shiramizu B: Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease. Pediatr Blood Cancer; 2008 Aug;51(2):193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease.
  • BACKGROUND: The mechanisms responsible for resistant disease or recurrence of non-Hodgkin lymphoma (NHL) in children cover a wide spectrum from drug resistance to genetic mutations.
  • A unique mechanism suggesting the role of mitochondria as the key energy source is studied following a clinical observation where pediatric Burkitt lymphoma (BL) specimens from patients on therapy were found to have increased copies of mitochondria DNA (mtDNA) in specimens which were shown to be positive for minimal residual disease and/or persistent disease (MRD/PD).
  • This study hypothesized that the mitochondria play an important role in a cell's recovery from toxicity via a compensatory increase in mtDNA.
  • PROCEDURE: BL specimens with MRD/PD were assayed for mtDNA.
  • An in vitro model was then designed using Ramos cell lines by exposing the lymphoma cells to varying concentrations of doxorubicin and vincristine for 1 hr; and allowing for recovery in culture over 7 days.
  • RESULTS: Increased mtDNA copy numbers were found in clinical specimens with MRD/PD as well as in recovering Ramos cells from chemotoxicity.
  • CONCLUSIONS: The recovering lymphoma cells from the chemotoxic effects appeared to compensate by increasing mtDNA content, which may contribute to the clinical residual or resistant disease in some cases of childhood BL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1691-5 [10557040.001]
  • [Cites] Vopr Onkol. 2006;52(4):398-403 [17024810.001]
  • [Cites] Forensic Sci Int. 2002 Mar 28;126(1):34-9 [11955829.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1339-45 [12429986.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13 [12571460.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1437-47 [12886229.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1109-13 [12921949.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] FEBS Lett. 1995 Oct 16;373(3):285-90 [7589484.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8512-5 [15623632.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Apr;37(4):822-34 [15694841.001]
  • [Cites] Mol Interv. 2005 Apr;5(2):94-111 [15821158.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):104-10 [15921730.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Antivir Ther. 2005;10 Suppl 2:M83-9 [16152709.001]
  • [Cites] Cell Mol Biol Lett. 2005;10(4):721-32 [16341280.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):295-309 [16324833.001]
  • [Cites] Genet Mol Res. 2006;5(1):55-62 [16755497.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1455-9 [17627010.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1035-9 [17979806.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):831-8 [17637738.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • (PMID = 18322926.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121955; United States / NCI NIH HHS / CA / R21 CA121955; United States / NCI NIH HHS / CA / R21 CA121955-01; United States / NCI NIH HHS / CA / CA121955-01; United States / NCI NIH HHS / CA / R21 CA121955-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Mitochondrial; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ NIHMS95130; NLM/ PMC2652580
  •  go-up   go-down


85. Fellows EA, Keene FR: Influence of anions on intervalence charge transfer (IVCT) in mixed-valence dinuclear complexes. J Phys Chem B; 2007 Jun 21;111(24):6667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spectroelectrochemical studies of the intervalence charge transfer (IVCT) characteristics of both diastereoisomeric forms of the dinuclear complex [{Ru(bpy)2}2(mu-dpi-)]n+ [bpy=2,2'-bipyridine; dpi-=4,5-di(2-pyridyl)imidazolate] showed that the degree of inter-metal electronic coupling (or valence delocalization) is dependent on stereochemical identity.
  • In a comparative investigation of electrochemical and spectroelectrochemical techniques of the anion-induced electron localization in [{Ru(bpy)2}2(mu-dpo)]5+ [dpo=3,4-di(2-pyridyl)-1,2,5-oxadiazole], differences were observed between the two methods in the order and extent of effects induced by a number of inorganic anions (PF6-, BF4-, ClO4-).
  • Comparative electrochemical studies were undertaken on [{M(bpy)2}2(mu-BL)]n+ {M=Ru, Os; BL=dpo, dpi-), which revealed substantial differences in DeltaEox (the separation between the redox potentials for the MII-MII/MIII-MII and MII-MIII/MIII-MIII couples) for the two metal centers and therefore the comproportionation constant Kc, dependent on the neutral or anionic nature of the bridging ligand.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388473.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Nileshwar A, Garg V: Comparison of Bullard laryngoscope and short-handled Macintosh laryngoscope for orotracheal intubation in pediatric patients with simulated restriction of cervical spine movements. Paediatr Anaesth; 2010 Dec;20(12):1092-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Bullard laryngoscope and short-handled Macintosh laryngoscope for orotracheal intubation in pediatric patients with simulated restriction of cervical spine movements.
  • AIM: To compare time to intubation, time to optimal laryngoscopy, best laryngeal view, and success rate of intubation with pediatric Bullard laryngoscope and short-handled Macintosh laryngoscope in children being intubated with neck stabilization.
  • BACKGROUND: Securing airway of a patient with restricted cervical spine movement has been a challenge faced by anaesthesiologists around the world.
  • Macintosh laryngoscope with manual inline stabilization is most commonly used.
  • Bullard laryngoscope is also useful in this situation as minimal neck movement occurs with its use.
  • Patients were randomly allocated to one of two groups: Group MB (first laryngoscopy using short-handled Macintosh laryngoscope followed by pediatric Bullard laryngoscope) and Group BM (first laryngoscopy using pediatric Bullard laryngoscope followed by short-handled Macintosh laryngoscope) with manual inline stabilization after induction of anesthesia and paralysis.
  • RESULTS: Laryngeal view when obtained was always Grade 1 with Bullard laryngoscope (38/38) when compared to Macintosh laryngoscope [Grade 1 (10/40)].
  • The mean time to laryngoscopy (and intubation) was shorter with Macintosh laryngoscope [15.53 s (38.15 s)] than Bullard laryngoscope [35.21 s (75.71 s)], respectively.
  • Success rate of intubation was higher with Macintosh laryngoscope (100%) when compared to Bullard laryngoscope (70%).
  • CONCLUSIONS: Laryngoscopy and intubation is faster using a short-handled Macintosh laryngoscope with a higher success rate compared to pediatric Bullard laryngoscope in pediatric patients when manual inline stabilization is applied.
  • [MeSH-major] Immobilization. Intubation, Intratracheal / instrumentation. Laryngoscopes. Laryngoscopy / instrumentation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21199118.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  •  go-up   go-down


87. Omoregie FO, Saheeb BD, Onasanya PO: Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature. Afr J Med Med Sci; 2008 Sep;37(3):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature.
  • This article reports two cases of periradicular Burkitt's lymphoma from Nigeria, to emphasize the difficulties in differentiating the early lesion from other periradicular lesions with similar clinical and radiological findings Case 1, is a 4-year-old boy who presented with a one-month history of a painless, hard, posterior mandibular swelling (right), which was causing loosening and displacement of deciduous teeth (84 and 85).
  • Histopathological examination of periradicular tissues from extracted tooth (85), confirmed the diagnosis of early periradicular B urkitt's lymphoma.
  • Case 2, is a 6-year-old boy who presented with one-week history of a loose, extruded right mandibular first molar tooth (46) and an exfoliated left mandibular first molar tooth (36).
  • Incisional biopsy of the oral lesion at the region of exfoliated left first mandibular molar (36) was useful for histopathological diagnosis of early Burkitt's lymphoma of the jaw.
  • In the face of limited diagnostic tools such as clinico-radiological assessment, cytology or incisional biopsy for incipient periradicular lesions, a high index of suspicion of Burkitt's lymphoma of the jaw may be helpful in early diagnosis and treatment of a lesion, presenting in a child as periradicular radiolucency or mixed radiolucency and radiopacity, with associated loosening and displacement of teeth.
  • [MeSH-major] Burkitt Lymphoma / pathology. Jaw Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982822.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Zainina S, Cheong SK: Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3). Clin Lab Haematol; 2006 Aug;28(4):282-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3).
  • Myelodysplastic syndrome (MDS) is recognized as a preleukaemic disorder with a variable risk of transformation to acute myeloid leukaemia.
  • Usually the blast cells in leukaemia are transformed after MDS displays a myeloid phenotype.
  • Even though lymphoid progression had been reported previously, most displayed myeloid-lymphoid hybrid or early B phenotype.
  • We report a case of an elderly man who had MDS transformed into Acute Lymphoblastic Leukaemia (ALL:L3) which is a rare lymphoid transformation.
  • [MeSH-major] Anemia, Refractory / pathology. Burkitt Lymphoma / pathology. Cell Transformation, Neoplastic / pathology


89. Clybouw C, Hadji A, ElMchichi B, Auffredou MT, Leca G, Vazquez A: BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. Biochem Biophys Res Commun; 2009 May 22;383(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA.
  • Indeed, expression of a BimEL cDNA leads in Hela cells leads to the production of both BimEL and BimL proteins.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Burkitt Lymphoma / genetics. Gene Expression Regulation, Leukemic. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcr / metabolism. RNA Splicing
  • [MeSH-minor] Cell Line, Tumor. Humans. Introns / genetics. Protein Biosynthesis / genetics. RNA, Messenger / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332026.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


90. Moffett PM, Baker BL, Kang CS, Johnson MS: Evaluation of time required for water-only decontamination of an oil-based agent. Mil Med; 2010 Mar;175(3):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 30 sec a black light was used by three evaluators to determine whether the agent was removed.
  • CONCLUSION: Whereas the data suggest the possibility of rapid water-only decontamination, the applicability of this data in current form is doubtful, but provides a model as a basis for future study.

  • MedlinePlus Health Information. consumer health - Biodefense and Bioterrorism.
  • MedlinePlus Health Information. consumer health - Chemical Emergencies.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20358708.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemical Warfare Agents; 0 / Oils; 059QF0KO0R / Water
  •  go-up   go-down


91. Meng JY, Zhang CY, Lei CL: A proteomic analysis of Helicoverpa armigera adults after exposure to UV light irradiation. J Insect Physiol; 2010 Apr;56(4):405-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proteomic analysis of Helicoverpa armigera adults after exposure to UV light irradiation.
  • Ultraviolet (UV) light (blacklight), which emits UV in the range of 320-400nm, has been used worldwide in light trapping of insect pests.
  • To gain a better understanding of the response of Helicoverpa armigera adults to UV light irradiation, we carried out a comparative proteomic analysis.
  • Three-day-old adults were exposed to UV light for 1h.
  • This study is the first analysis of differentially expressed proteins in phototactic insects under UV light irradiation conditions and gives new insights into the adaptation mechanisms responsive to UV light irradiation stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19944107.001).
  • [ISSN] 1879-1611
  • [Journal-full-title] Journal of insect physiology
  • [ISO-abbreviation] J. Insect Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insect Proteins
  •  go-up   go-down


92. Kimura M, Kagawa T: Blue light-induced chloroplast avoidance and phototropic responses exhibit distinct dose dependency of PHOTOTROPIN2 in Arabidopsis thaliana. Photochem Photobiol; 2009 Sep-Oct;85(5):1260-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue light-induced chloroplast avoidance and phototropic responses exhibit distinct dose dependency of PHOTOTROPIN2 in Arabidopsis thaliana.
  • PHOTOTROPIN2 (PHOT2) is a unique photoreceptor involved in chloroplast avoidance movement and also regulates blue light (BL) responses, such as phototropism and leaf flattening, together with PHOTOTROPIN1 (PHOT1) in Arabidopsis thaliana.
  • In the present study, we examined PHOT2 dose dependency of BL responses using the phot1-5 phot2-1 double mutant expressing an AtPHOT2-GFP (P2G) fusion protein.
  • Chloroplast avoidance and phototropic responses of P2G transgenic lines were enhanced in a manner dependent on the P2G levels, whereas the leaf flattening phenotype was simply complemented by P2G equivalent to the wild type (WT) PHOT2 level.
  • The chloroplast avoidance velocity of P2G transgenic lines exhibited enhanced sensitivity to BL in comparison with WT.
  • These results collectively indicate that each BL response has distinct threshold levels of PHOT2 requirement.
  • [MeSH-major] Arabidopsis / physiology. Arabidopsis Proteins / physiology. Chloroplasts / physiology. Light

  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453386.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabidopsis Proteins
  •  go-up   go-down


93. Chen Y, Peng C, Li D, Li S: Molecular and cellular bases of chronic myeloid leukemia. Protein Cell; 2010 Feb;1(2):124-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and cellular bases of chronic myeloid leukemia.
  • Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the overproduction of granulocytes, which leads to high white blood cell counts and splenomegaly in patients.
  • Based on clinical symptoms and laboratory findings, CML is classified into three clinical phases, often starting with a chronic phase, progressing to an accelerated phase and ultimately ending in a terminal phase called blast crisis.
  • Blast crisis phase of CML is clinically similar to an acute leukemia; in particular, B-cell acute lymphoblastic leukemia (B-ALL) is a severe form of acute leukemia in blast crisis, and there is no effective therapy for it yet.
  • However, the inability of BCR-ABL kinase inhibitors to completely kill leukemia stem cells (LSCs) indicates that these kinase inhibitors are unlikely to cure CML.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Neoplastic Stem Cells / enzymology. Neoplastic Stem Cells / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] 5-Lipoxygenase-Activating Proteins / metabolism. Animals. Benzamides. Disease Models, Animal. Humans. Imatinib Mesylate. Male. Mice. PTEN Phosphohydrolase / metabolism. Philadelphia Chromosome. Piperazines / therapeutic use. Point Mutation. Protein Structure, Tertiary. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21203982.001).
  • [ISSN] 1674-8018
  • [Journal-full-title] Protein & cell
  • [ISO-abbreviation] Protein Cell
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5-Lipoxygenase-Activating Proteins; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC4875160
  •  go-up   go-down


94. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


95. Karakayali H, Ozcay F, Sevmis S, Savas N, Haberal M: Liver transplantation for small babies. Transplant Proc; 2007 May;39(4):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for small babies.
  • Orthotopic liver transplantation remains a major medical and surgical challenge in small pediatric patients.
  • From April 2003 to June 2006, 21 small babies (each of whom weighed less than 10 kg or was younger than 1 year of age) underwent orthotopic liver transplantation.
  • Histological examination revealed hepatocellular carcinoma in 2 patients, and Burkitt's lymphoma in 1 patient.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524918.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Yun HS, Bae YH, Lee YJ, Chang SC, Kim SK, Li J, Nam KH: Analysis of phosphorylation of the BRI1/BAK1 complex in arabidopsis reveals amino acid residues critical for receptor formation and activation of BR signaling. Mol Cells; 2009 Feb 28;27(2):183-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The formation of a receptor complex in response to BRs and the subsequent activation of cytoplasmic domain kinase activity share mechanistic characteristics with animal receptor kinases.
  • In addition, transgenic wild type plants overexpressing BAK1(T455A) lost the phosphorylation activity normally exhibited in response to BL, leading to semi-dwarfism.
  • [MeSH-minor] Agrobacterium tumefaciens / growth & development. Agrobacterium tumefaciens / metabolism. Amino Acid Substitution. Brassinosteroids. Cell Membrane / metabolism. Mutation / genetics. Phosphorylation. Plants, Genetically Modified. Plasmids. Saccharomyces cerevisiae / growth & development. Saccharomyces cerevisiae / metabolism

  • COS Scholar Universe. author profiles.
  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277500.001).
  • [ISSN] 1016-8478
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Brassinosteroids; 0 / Cholestanols; 0 / Plant Growth Regulators; 0 / Steroids, Heterocyclic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / BAK1 protein, Arabidopsis; EC 2.7.11.1 / BRI1 protein, Arabidopsis; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; Y9IQ1L53OX / brassinolide
  •  go-up   go-down


97. Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL: Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma. Cancer Genet Cytogenet; 2006 Oct 15;170(2):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma.
  • Follicular lymphoma (FL) is the most common indolent or low-grade non-Hodgkin lymphoma (NHL).
  • Histologic transformation to high-grade lymphoma, generally to diffuse large B-cell lymphoma, occurs in 25-35% of cases.
  • We report the case of a 58-year-old patient who presented with stage IVA, grade 2 FL that subsequently transformed to Burkitt lymphoma.
  • A t(1;11)(q25;q13) was acquired simultaneously with t(8;22) and, in conjunction with other chromosomal abnormalities, coincided with an extremely aggressive clinical course.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations. Lymphoma, Follicular / genetics
  • [MeSH-minor] Bone Marrow / pathology. Chromosome Inversion. Disease Progression. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Lymph Nodes / pathology. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011985.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


98. Said J: Diffuse aggressive B-cell lymphomas. Adv Anat Pathol; 2009 Jul;16(4):216-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse aggressive B-cell lymphomas.
  • Diffuse aggressive B-cell lymphomas comprise a relatively common and increasingly diverse group of neoplasms.
  • At the same time there is increasing understanding of the overlap, which occurs in the grey zone between diffuse large B-cell lymphoma and Burkitt lymphoma as well as between diffuse large B-cell lymphoma and Hodgkin lymphoma.
  • This review aims to provide practical insights in the correct identification and differential diagnosis of these lymphomas, with emphasis on the changes that have occurred with the publication of the 2008 World Health Organization updated classification.
  • [MeSH-major] Biomarkers, Tumor. Burkitt Lymphoma / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Bone Marrow Examination. Diagnosis, Differential. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. Predictive Value of Tests. Stromal Cells / pathology. World Health Organization

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546610.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 147
  •  go-up   go-down


99. Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA: Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol; 2007 Nov;4(3):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr Virus (EBV) infection induces cellular non-coding (nc)RNAs e.g., the "vault" RNAs or miRNAs such as miR-21, miR-155 or miR-146a.
  • MiR-146a is upregulated in various tumours and plays a role in innate immunity.
  • Northern blotting revealed high levels of miR-146a and miR-155 in the Burkitt's lymphoma cell line Jijoye which expresses LMP1 while the LMP1-deficient P3HR1 mutant derived from Jijoye expresses less miR-146a or miR-155.
  • Likewise, EBV-latency type I Burkitt's lymphoma cells with low LMP1 levels also contain low levels of either miR-146a or miR-155 while their levels are increased in LMP1-expressing EBV-latency type III BL cells.
  • It is possible that the induction of miR-146a plays a role in the induction or maintenance of EBV latency by modulating innate immune responses to the virus infected host cell.
  • [MeSH-minor] B-Lymphocytes / immunology. B-Lymphocytes / metabolism. B-Lymphocytes / virology. Base Sequence. Burkitt Lymphoma / immunology. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / virology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Humans. Molecular Sequence Data. NF-kappa B / physiology. Virus Latency / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347435.001).
  • [ISSN] 1555-8584
  • [Journal-full-title] RNA biology
  • [ISO-abbreviation] RNA Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / MIRN146 microRNA, human; 0 / MicroRNAs; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  •  go-up   go-down


100. Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Suzuki A, Saigo K, Kawano S, Takenokuchi M, Kumagai S, Matsuo Y, Koizumi T, Takeuchi M: Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21). Eur J Haematol; 2005 Jan;74(1):11-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21).
  • AIM: Acute lymphoblastic leukemia (ALL) with L2 (FAB) morphology has rarely been reported to show t(14;18)(q32;q21).
  • We aimed to delineate the stage at which this type of ALL is derived in B-lineage differentiation.
  • METHODS: The somatic hypermutation (SHM) of the variable region of immunoglobulin heavy chain (IgV(H)) gene and the expression of terminal deoxynucleotidyl transferase (TdT), recombination-activating gene 1 and 2 (RAG-1 and -2), and activation-induced cytidine deaminase (AID) were investigated in three cell lines and two fresh samples, including a pair of matched fresh and cell line cells.
  • SHM of the IgV(H) gene was found in all samples with high average frequency (11.84%) comparable with that in follicular lymphoma.
  • CONCLUSION: As AID and SHM are generally regarded as properties exhibited by mature B cells, the presence of AID and SHM in this study seems to be incompatible with the general understanding of the early stage derivation of ALL in B-lineage differentiation.
  • The results here give some insight into the relationship between disease type (ALL or lymphoma) and derivation stage, the overlapping of the early stage phenotype and the mature genomic characteristics, and the probable relationship between the mechanism of the occurrence of t(14;18)(q32;q21) and the machinery causing SHM.
  • [MeSH-major] Cytosine Deaminase / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Somatic Hypermutation, Immunoglobulin
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Cytidine Deaminase. DNA Nucleotidylexotransferase / genetics. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Gene Expression. Genes, RAG-1. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Nuclear Proteins. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613101.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / V(D)J recombination activating protein 2; EC 2.7.7.31 / DNA Nucleotidylexotransferase; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.1 / Cytosine Deaminase; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down






Advertisement